Aging and sex hormones in males

Maria Chiara Decaroli and Vincenzo Rochira

ABSTRACT
Several large cohort studies have disclosed the trajectories of sex steroids changes overtime in men and their clinical significance. In men the slow, physiological decline of serum testosterone (T) with advancing age overlaps with the clinical condition of overt, pathological hypogonadism. In addition, the increasing number of comorbidities, together with the high prevalence of chronic diseases, all further contribute to the decrease of serum T concentrations in the aging male. For all these reasons both the diagnosis of late-onset hypogonadism (LOH) in men and the decision about starting or not T replacement treatment remain challenging. At present, the biochemical finding of T deficiency alone is not sufficient for diagnosing hypogonadism in older men. Coupling hypogonadal symptoms with documented low serum T represents the best strategy to refine the diagnosis of hypogonadism in older men and to avoid unnecessary treatments.

KEYWORDS
bone mineral density; estradiol; late-onset hypogonadism (LOH); menopause; replacement treatment; sex steroids; testosterone

Introduction
Aging is associated with changes in the physiological functioning of the endocrine system. Except for the thyrotropin hormone (TSH) that tends to increase with advancing age, the secretion of other pituitary hormones such as growth hormone (GH) and prolactin progressively decreases with aging. The same happens to insulin-like growth factor-1 (IGF-1), which is directly regulate by GH.

The aging of the reproductive function is characterized by the loss of function of gonads that occurs as an on/off phenomenon in females at the time of menopause. (Fig. 1). Vice versa, in aging males, the reproductive function progressively declines in parallel with the decrease of testicular function year by year. Accordingly, gonadotropins slightly increase in men while definitely soar at the time of menopause in women. In men, however, also a decline of gonadotropic cell function has been documented in a significant percentage of aging men.

As far as sex hormones are concerned, it should be remarked that their production is different in men and women during adulthood: serum testosterone (T) is 10 folds higher in men than in women, while serum estradiol (E2) declines after the fifties in both sexes; thus sex hormones changes during aging differ by gender (Fig. 1). Gender differences in aging related decline of sex hormones are outlined in Figure 1.

Physiological decline of serum T with advancing age in men
Serum total T declines with advancing age with a rate that has been estimated to be about 1–2% per year from the third decade onward. (Fig. 1). This rate of decline in serum T corresponds approximately to a reduction of 3.2–3.5 ng/dL (0.110–0.121 nmol/L) per year. At the age of 75 y a men has already lost about 30% of his circulating quote of T measured at the age of 25 years. According to different studies, the prevalence of low total T in men over 60 y is, on average, around 20% to 30% and it constantly increases with aging.

The total amount of circulating serum T corresponds to the total serum T usually assayed into the clinic, which is the sum of both free T and T bound to serum proteins. Serum free T represents the circulating fraction that is completely unbound and promptly available for binding the androgen receptor in target tissues; it is, however, a small part of circulating serum T. A minimal part of circulating T binds albumin and the strength of this binding is weak. For this reason, serum
free T and T bound to albumin—in other words the T not bound to Sex Hormone Binding Globulin (SHBG)—represent the bioavailable T\(^1\). *Vice versa* T bound to SHBG is not promptly available for binding to the androgen receptor due to the high strength of the binding; this represents the amount of circulating T which is not bioavailable.\(^7\,11\,14\) Since bioavailable serum T is more available to the cells compared with SHBG-bound serum T, information on changes in both serum free and bioavailable T during aging is of relevance.\(^14\) SHBG increases with advancing age of about 2.7% per year,\(^4\,15\,16\) and accounts for an even larger decline in serum bioavailable T (3 to 4% per year) compare with total T in the elderly man.\(^5\) In addition, several factors (e.g. obesity)\(^17\,20\) and/or comorbidities,\(^21\,22\) which become common with advancing age, might modify in percentage amount amount of different T fractions.\(^7\)

Several methods are available to measure the different fractions of circulating T. Total serum T is the fraction most commonly measured in clinical practice and is usually assayed with Immunoassays (IAs) in clinical laboratories.\(^12\,23\,25\) Mass spectrometry (MS), particularly liquid chromatography-tandem mass spectrometry (LC-MS/MS),\(^26\) is considered the gold standard for the measurement of total serum T, but, at present, is mainly used for research purposes.\(^23\,27\) In general, results obtained with IAs do not reproduce in a reliable way those obtained with LC-MS/MS\(^28\) leading to the concept that commercially available IAs are widely inaccurate if compared with the gold standard.\(^24\,27\,30\) Accordingly, LC-MS/MS is able to lessen interferences, has better specificity, and reduce between-method bias.\(^31\) However, different results obtained by using different IAs are unimportant in the male, eugonal range, but becomes relevant when measuring T levels falling in the low male range.\(^23\,27\) In discordance with other studies,\(^27\) the comparison between serum total T measurements by using IAs or MS, which represents the gold standard for T levels measurement, has shown similar, highly-correlated results in the EMAS cohort.\(^22\) This means that IAs could be considered a good method for the evaluation of total serum T in clinical practice also for distinguishing between eugonadism and hypogonadism in the clinical setting.\(^22\) This issue is crucial for the diagnosis of male hypogonadism and is still controversial (see the paragraph below on the diagnosis of male hypogonadism in aging). In general, for clinical purposes it is important to validate the assay and to perform continuous quality control, independently from the methodology used.\(^23\,29\,30\,33\) Furthermore, in the last few years, LC-MS/MS is becoming more and more available in the clinical setting and this evolving scenario is expected to be implemented, especially in clinical laboratories able to provide high throughput outcomes thanks to the procedural low costs that allows saving money for each assay and writing off expenses due to initial purchase of technological equipments.\(^23\)

The measurement of free serum T might be performed by means of equilibrium dialysis or ultrafiltration methods, which are, however, not manageable in clinical practice or, alternatively, by the use of direct free T assays, which are unreliable and strongly inaccurate.\(^23\,24\) The better way to have an esteem of free serum T is to calculate free serum T starting from the value of total serum T and the measurement of both SHBG and albumin.\(^7\,13\,23\,24\) Even though it is well known that calculated free T overestimates the value obtained by equilibrium dialysis,\(^14\) it remains largely employed both for research and clinical purposes.

Techniques for the measurement of bioavailable serum T are based on previous precipitation and separation of SHBG-bound T. For this reason, these methods are not simple and are not routinely employed in clinical laboratories. In addition, it is not clear the advantage of measuring bioavailable T rather than free T\(^23\). Starting from available data of serum albumin, SHBG, and total T, it is possible to calculate free and bioavailable serum T by using a simple formula and a calculator widely available on the web (http://www.issam.ch/freetesto.htm). By taking into account all the issues mentioned before, it becomes clear that the comparison of the results coming from different studies suffers from bias due to methodological differences when measuring serum T and its decline during aging.

As serum T varies during the day\(^34\) and seasonally,\(^25\,35\,36\) it should be assayed in the morning and low

---

### Figure 1.
Serum levels of both testosterone (T) (solid lines) and estradiol (E\(_2\)) (broken lines) across the lifespan in men (blue lines) and women (pink lines). Data used for plotting age-related sex steroids changes in both sexes have been derived from Kaufman & Vermeulen 2005,\(^5\) Zmuda et al. 1997 (for men), and from Al-Saef et al. 2000\(^2\) and Veldhuis 2013 (for women). Serum E\(_2\) levels of premenopausal women are represented as the mean of E\(_2\) measured during the different phases of the menstrual cycle; T: testosterone; E\(_2\): estradiol.
values need to be confirmed twice in 2 different serum samples, the second one being obtained at least after 2 to 4 weeks after first T determination. Differences in timing serum samples for T determination might also account for discrepant results obtained in different research settings.

In addition, the decline of both total and free serum T shows of course a high degree of interindividual variability accounting for serum T within the normal range in most of the elderly patients (> 60 years) and below the normal range in about 20% of them.

Several risk factors have been associated with serum T decline. Among them ethnicity, age, anthropometry, lifestyle factors, other concomitant comorbidities, chronic diseases, critical acute illnesses, drugs and/or other treatments should be taken into account. The main risk factors or clinical conditions associated with low serum T are listed in Table 1.

### Relationship between T decline and estradiol E2

Longitudinal studies have shown that serum E2 declines in parallel with serum T in men. It is well known that serum E2 rather than T is important for bone health. Thus, the decline of serum T in older men becomes particularly harmful for the bone only when also serum E2 decreases. In particular serum E2 should decrease below a threshold which is in-between 15 and 25 pg/mL (55.1–91.8 pmol/L).

Apart from the role of E2 on bone, other several physiological functions have been attributed mainly to E2. Among them, the inhibitory effect of T on the hypothalamus and the pituitary seems to be due to a greater extent to its conversion into estrogens. Furthermore, also sexual function, especially sexual desire, is in part dependent from E2 too. Accordingly, serum E2 is directly related to sexual desire in men.

### Age-related male hypogonadism: Results from large cohorts studies involving middle-aged to older men

One of the first studies investigating serum T in aging men by a longitudinal design was the New Mexico Process Study that followed preliminary data previously obtained by cross-sectional studies. Previous data were contradictory and came from observational studies mainly based on inpatients with a poor health status, thus they were not representative on average of an aging population of men. After the above mentioned study, several other studies on large cohort of aging men were prospectively performed. Of them, the main are: the Baltimore Longitudinal Study of Aging (BLSA), the Massachusetts Male Aging Study (MMAS), the Osteoporotic Fractures in Men Study (MrOS), the European Male Aging Study (EMAS), the Rancho Bernardo Study (RBS), the InCHIANTI Study, the Tromsø Study, the Concord Health and Aging in Men Project (CHAMP), the Health in Men Study (HIMS). The main characteristics of these studies are all summarized in Table 2. All these studies differ each other for several aspects, including the main aim of the study (that not always is specifically addressed to the study of sex hormones decline during aging), the involvement of subjects of both genders, the duration of the study, and the number of participants (Table 2). As expected, also the methodological approach differ among studies both in terms of methods used for the assessment of circulating sex steroids, the type of sex steroid assayed (estradiol is not available from all the studies), the study design, and the clinical investigations included in the study protocol, the latter varying widely among studies according to their primary and secondary endpoints (Table 3, Table 4). Even though

---

**Table 1. Risk factors involved in serum T decline in aging men.**

| Risk factors and predictors of T deficiency: |
|------------------------------------------|
| **General factors:** Age, ethnicity, poor health status and frailty, progressive decrease of number and function of Leydig cells. |
| **Metabolic and anthropometric factors:** BMI, weight, waist circumference, visceral adiposity. |
| **Life-style habits:** excessive alcohol intake, cigarette smoking, sedentary lifestyle. |
| **Comorbidities:** hypertension, metabolic syndrome. |
| **Chronic Diseases:** moderate to severe chronic obstructive pulmonary disease, HIV, chronic liver diseases, chronic renal failure (especially end-stage and hemodialysis), type 2 diabetes, hypopituitarism, rheumatoid arthritis, Hodgkin disease. |
| **Critical Acute illness** |
| **Pharmacological and other treatments:** opiates, glucocorticoids, inhibitors of T synthesis (e.g., mitotane, ketoconazole), chemotherapy, testicular irradiation, GnRH analogs. |

**Note.** T: testosterone; BMI: body mass index; GnRH: gonadotropin-releasing hormone.
the comparison among all these studies goes beyond the aim of this review, we will try to report in a critical fashion the aspects that are more relevant for the comprehension of the relationship between sex hormones and aging in males.

**Main characteristics of large cohort studies**

The BLSA is a longitudinal study on human aging, which began in 1958 (https://www.blsa.nih.gov/about/history/); it is the oldest study taking into account sex steroids changes during aging in men and is based on enrollment of participants with different ages who are followed afterward all lifelong.58 This is one of the biggest studies on aging showing T levels decline in men and its relationship with several aspects related to aging4 (Table 2). Other than BLSA, also the RBS and the Tromsø Study are very old, being started in the 70s (Table 2).59,60

Among studies that have specifically investigated the decline of sex steroids, particularly T, in middle-aged to older men, the MMAS is one of the pioneering study, the investigation of sex hormones changes in aging being the main study endpoint (Table 2).53,61 The MrOS study is a multicenter study enrolling around 6000 men older than 65 y in order to identify risk factors for fractures in older men (Table 2).62 By enrolling men also from Sweden and Hong Kong, the study has reached a considerable number of participants (Table 2). The main aim of the study, however, was to evaluate the association between sex hormones levels and osteoporosis rather than overtime changes during aging (Table 2).62

The EMAS (http://www.emas.man.ac.uk) is a multicenter (involving 8 European centers) cohort study that has been pointedly designed in order to evaluate physical, psychological and endocrine changes overtime, with particular attention to modifications of T secretion occurring with aging.63,64 (Table 2).

The Rancho Bernardo Study started as a survey of heart disease risk factors in adults who were older than 30 y and lived in the southern California community of Rancho Bernardo, that has progressively accumulated a lot of data (not only on CV system) from this cohort across the last 40 years59,65 (Table 2).

The InCHIANTI study involves older people living in the Chianti geographic area (Tuscany, Italy) (http://inchiantistudy.net/wp/). For the majority of men, measurements of total T, E2 and SHBG serum levels were available, even though the main aim of the study was not strictly related to hormonal changes overtime66-70 (Table 2).

The Tromsø study (https://en.uib.no/prosjekter/prosjekt?p_document_id=80172) is composed by several surveys performed in sequence and collecting information that have changed overtime across different surveys66,71,72 The fourth survey was taken between 1994 and 1995; all inhabitants of Tromsø (Northern Norway) older than 24 y were invited and, between the subjects who accepted to take part to the study, all men aged 55–74 y and random samples of the other age groups were involved and hormonal measurements performed66 (Table 2).

The CHAMP study was originally designed in order to investigate the health status in men older than 70 y living in a defined geographical region near the Concord Hospital in Sydney.73-75 The study paid particular attention to the effects of age-related sex hormones decline.73 After a baseline assessment; a subsequent, biennial follow up was then realized.73 A strength of this project is the use of LC-MS/MS for steroid assays, which represents currently the “gold standard”(Table 2).74,76,77

| Study | Period (yrs) | Study Design | Sex M, F | Subjects (N)* | Age | Span (yrs) | T assay** | Sex Steroids as Main Aim | Primary End Point* | Country |
|-------|-------------|--------------|---------|---------------|-----|------------|-----------|-------------------------|------------------|---------|
| BLSA  | 1958-       | PLOC-B       | M,F     | n.a.          | >20 | 58         | IAs       | no                      | General overview on aging | Baltimore (USA) |
| MMAS  | 1987–2004   | PLOC-B       | M       | 1709          | 40–70 | 17        | IAs       | yes                     | Hormone levels and ED Fracture risk factors | Boston (USA) |
| MrOS  | 2000–2006   | MC-PLOC-B    | M       | ~11000        | >65 | 6         | LC-MS/MS  | no                      |                      | USA, Sweden, Hong-Kong |
| EMAS  | 2003–2010   | MC-PLOC-B    | M       | 3369          | 40–79 | 7         | LC-MS/MS  | yes                     | Anabolic hormones changes and health outcomes | Some EU Countries |
| RBS   | 1972-       | PLOC-B       | M,F     | 1094          | >30 | 44        | IAs       | no                      | Heart disease risk factors | Southern California (USA) |
| InCHIANTI | 1998-      | PLOC-B       | M,F     | 601           | >65 | 18        | IAs       | no                      | Physical function in aging | Tuscany (Italy) |
| Tromso| 1974–2008   | PLOC-B       | M,F     | 6595          | n.d. | 34        | IAs       | no                      | CV-related mortality | Tromso (Norway) |
| CHAMP | 2005-       | PLOC-B       | M       | 1705          | >70 | 11        | LC-MS/MS  | no                      | Major geriatric syndromes | Sydney (Australia) |
| HIMS  | 1996–2004   | P-BRT        | M       | 12203         | >65 | 8         | IAs       | no                      | Aortic aneurysm in aging | Perth (Australia) |

Notes. M: males; F: females; *Number of male participants at the beginning of the study; **For some studies methods for T assay varied overtime during the long period of study protocol; 1UK, Italy, Belgium, Poland, Sweden, Spain, Hungary, Estonia; EU: European; *^*The main end point to be investigated in relation to aging; PLOC-B: Prospective, Longitudinal, Observational, Community-Based Study; MC-PLOC-B: MultiCenter, Prospective, Longitudinal, Observational, Community-Based Study; P-BRT: Population-Based, Randomized, Trial; n.d.: not detectable at any analysis; CV: cardiovascular; ED: erectile dysfunction.
Table 3. Main outcomes from large cohort studies investigating sex steroid changes occurring in aging.

| Outcomes                                      | BLSA       | MMAS       | MrOS       | EMAS       | RBS        | In CHIANTI | Tromsø     | CHAMP       | HIMS       |
|-----------------------------------------------|------------|------------|------------|------------|------------|------------|------------|-------------|------------|
| Total T decline (per year)                    | Yes (3.2 ng/dl) | Yes (1.6%) | n.a.       | Yes        | Yes (1 pg/ml) | n.a.       | Yes        | Yes (2% per year) | No         |
| T-free/bioavailable decline (per year)        | Yes        | Yes (2–3%) | Yes        | Yes        | Yes (18.5 pg/ml) | n.a.       | Yes        | Yes         | Yes        |
| SHBG increase                                 | Yes        | Yes        | n.a.       | Yes        | Yes (1.9 pg/ml) | n.a.       | Yes        | No          | Yes        |
| E2 decline (per year)                         | n.a.       | n.a.       | n.a.       | Yes        | n.a.       | n.a.       | n.a.       | n.a.        | n.a.       |
| Sexual desire decline                         | Associated to ↓T and ↓fT | n.a.       | Associated to ↓fT | n.a.       | Associated to ↓fT | n.a.       | Associated to ↓fT | Associated to ↓SHBG and ↓fT | n.a.       |
| Erectile function decline                     | Associated to ↓E2; conflicting data about T and ↓SHBG | Associated to ↓E2 but not to T | Associated to ↓bioavailable E2 and T | Associated to ↓SHBG but not with T and E2 | Not associated to TT, fT, E2 | Not associated to TT, fT, E2 | Not associated to sex steroids | n.a.       |
| BMD impairment                                | Associated to ↓fT | n.a.       | Associated to ↓fT | n.a.       | Associated to ↓fT | n.a.       | Associated to ↓fT | Associated to ↓SHBG and ↓fT | n.a.       |
| Increased fracture risk                       | Associated to ↓fT | n.a.       | Associated to ↓fT | n.a.       | Associated to ↓fT | n.a.       | Associated to ↓fT | Associated to ↓fT and ↓TT | n.a.       |
| Lean mass and muscle strength decline         | Associated to ↓fT | n.a.       | Associated to ↓fT | n.a.       | Associated to ↓TT | n.a.       | Associated to ↓TT | Associated to ↓TT and ↓fT | n.a.       |
| Physical performance decline                  | Associated (weakly) to ↓TT | n.a.       | Associated to ↓fT | n.a.       | Associated to ↓fT | n.a.       | Associated to ↓fT | Associated to ↓fT | n.a.       |
| Frailty increase                              | Associated to ↓TT | n.a.       | Associated to ↓TT | n.a.       | Associated to ↓TT | n.a.       | Associated to ↓TT | Associated to ↓TT | n.a.       |
| Overweight and obesity increase               | Associated to ↓TT and ↓SHBG | Associated to ↓TT, ↓fT, and ↓SHBG | n.a.       | Associated to ↓TT, ↓fT, and ↓SHBG | n.a.       | Associated to ↓TT, ↓fT, and ↓SHBG | n.a.       | Associated to ↓TT (if BMI>25) | n.a.       |
| Metabolic Syndrome risk                       | Associated to ↓TT and ↓SHBG | Associated to ↓TT and ↓SHBG | n.a.       | n.a.       | n.a.       | n.a.       | n.a.       | Associated to ↓TT and ↓SHBG, and ↑E2 | n.a.       |
| Diabetes risk                                 | n.a.       | Associated to ↓TT and ↓SHBG | n.a.       | n.a.       | Associated to ↓TT, ↓fT | n.a.       | ↑TT and ↑SHBG are protective | n.a.       | n.a.       |
| CV risk increase                              | Arterial stiffness associated to ↓TT | n.a.       | Atherosclerosis associated to ↓TT | Hypertension associated to ↓TT | Hypertension associated to ↓TT | Artery disease associated to ↑SHBG, not to T and E2 | Hypertension and carotid atherosclerosis associated to ↓TT | n.a.       | n.a.       |
| Low T association with poor health status and unhealthy habits | Alcohol intake associated to ↓TT | n.a.       | n.a.       | n.a.       | n.a.       | n.a.       | Smoking associated to ↓TT, ↑fT, ↑SHBG | Self-reported poor status associated to ↓TT, ↓fT, ↓SHBG | n.a.       |
| Low T associated to reduced hemoglobin        | n.a.       | n.a.       | yes        | n.a.       | yes        | n.a.       | n.a.       | n.a.        | n.a.       |

(continued on next page)
| Outcomes                                      | BLSA | MMAS | MrOS | EMAS | RBS | In CHIANTI | Tromsø | CHAMP | HIMS |
|----------------------------------------------|------|------|------|------|-----|------------|--------|-------|------|
| Low T associated to dyslipidemia             | n.a. | n.a. | n.a. | yes  | yes | n.a.       | yes    | n.a.  | n.a. |
| Increase of all-cause mortality risk with low T | no   | Weak association | yes | yes  | yes | yes \* | yes    | yes   | yes  |
| CV mortality risk increase associated to low T | n.a  | n.a. | n.a. | n.a. | yes | n.a.       | No     | Associated to \( \downarrow E_2 \) | Associated to \( \downarrow fT \) |
| Cognitive function decline associated to T   | Associated to \( \downarrow fT \) | Not associated to T | Associated to \( \uparrow \text{SHBG} \) | n.a. | n.a. | n.a.       | No associated to \( E_2, T, \) and \( \text{SHBG} \) levels | Not |
| Depressive mood increase                     | Not associated to T | n.a. | n.a. | n.a. | Associated to \( \downarrow \text{bioavailable T} \) | n.a. | n.a. | Associated to \( \downarrow \text{TT} \) |

**Notes.** TT: Total Testosterone; \( fT \): free Testosterone; \*Conflicting data (association with both total and free low T, but only in more recent analyses); \#muscle strength only, not muscle and lean mass; \^no correlation with low T alone, but with low T together with other hormones deficit; \^^correlation with both total and free low T and with low \( E_2 \).
Age-related sex steroids changes across cohort studies

Almost all the studies found a decline of total serum T with advancing age (Table 3, Table 4). The BLSA estimated a decline of total serum T around 3.2 ng/dl per year, with an esteem being around 1.9 pg/ml per year in the RBS, while the first data coming from the MMAS reported a decline of serum total and free T of about 0.4% and 1.2% per year, respectively (Table 3). More recently, the CHAMP study showed a decline of serum total T around 2% per year (Table 3).

The EMAS results have confirmed, in the last years, the data concerning the progressive decline in aging men of serum total T, free T, and E2, as well as those concerning the rise of SHBG with aging (Table 3).

The CHAMP recently replicated these results except for a surprising increase of E2 (Table 3).

In the HIMS study, serum free T significantly decreased with increasing age, while total serum T levels seemed to remain stable; this is probably due to the important increase of SHBG in older age, which could justify the persistence of stable total T levels (Table 3).

In line with other studies, also the RBS showed a decline of both total and bioavailable serum T levels with aging (Table 3). In particular, bioavailable serum T levels decreased more (18.5 pg/ml) than serum total T in aging men mainly due to the corresponding increase of SHBG with age (Table 3).

Even though the MrOS did not provide data on the trajectories of sex steroids overtime, it indirectly has confirmed that both serum T and E2 decline with advancing age (Table 3). By dividing participants according to quartiles of SHBG and sex steroids, in fact, their age was higher in the higher quartiles of serum SHBG and in the lower quartiles of both serum E2 and free T (Table 3).

Vice versa no data on the decline of sex steroids were available in the InChianti study even though measurements of total T, E2 and SHBG serum levels were available for the majority of men in this study hormonal data were mainly used for investigating the association between circulating sex steroids and several conditions that are common in aging (Table 3).

Male hypogonadism across cohort studies

The prevalence of biochemical hypogonadism seems always to increase with advancing age, being independently from the study considered, at the lowest in men younger than 49 y and progressively increasing through decades, with the highest prevalence being in men in
their 80s. However, according to a more recent analysis, total serum T levels seem to be quite stable until the age of 70 years, after that there would be a progressive, significant decline, while the bioavailable serum T seems to decline more linearly with aging.

In line with other studies, in the Tromsø study the investigation of hormonal changes with aging resulted in the finding of lower serum T levels and higher gonadotropins levels in older men (Table 3), even though the measurement of gonadotropins in aging men is scarcely helpful in predicting the future development of hypogonadism. Several cutoffs for male hypogonadism have been suggested on the basis of the results of these large cohort studies. The MMAS study has suggested the following age-related cutoffs for serum total T: 251, 216, 196, and 156 ng/dL (8.7, 7.5, 6.8, and 5.4 nmol/L) for men in their 40s, 50s, 60, and 70s, respectively. Many data about aging and gonadal status arose from the EMAS, and the identification and definition of the LOH as a clinical condition has been one of the biggest results. LOH has been in fact defined as a condition characterized by 3 sexual symptoms (decreased sexual thoughts, decreased frequency of morning erections, and erectile dysfunction) together with total serum T less than 317 ng/dL (8.7, 7.5, 6.8, and 5.4 nmol/L) for men in their 40s, 50s, 60, and 70s, respectively. Many data about aging and gonadal status arose from the EMAS, and the identification and definition of the LOH as a clinical condition has been one of the biggest results. LOH has been in fact defined as a condition characterized by 3 sexual symptoms (decreased sexual thoughts, decreased frequency of morning erections, and erectile dysfunction) combined with total serum T less than 317 ng/dL (8.7, 7.5, 6.8, and 5.4 nmol/L) for men in their 40s, 50s, 60, and 70s, respectively. According to the grade of serum T decrease, LOH can be considered as moderate or severe. In particular, total serum T concentrations lower than or equal to 230 ng/dL (8 nmol/L) have been associated with worse sexual function, and higher rates of erectile dysfunction.

**Main outcomes of cohort studies**

The comparison of such kind of large cohort studies clearly remarks the great heterogeneity of outcomes, which differ for each study according to the peculiarity of the study design and the number and type of clinical and laboratory data collected. While data on trajectories of sex steroids are almost available in all studies (see the paragraph above), information about the relationships among circulating sex steroids and/or various clinical aspects and physiological changes related to aging become patchy when moving across the various studies (Table 3).

While changes in circulating total, free, and bioavailable T, E2, and SHBG are unidirectional in almost all the studies, several other outcomes were not replicated, thus leading to conflicting results when different studies are compared each other (Table 3, Table 4).

The relationship between the decline of serum T and the worsening of sexual function has been investigated and confirmed by most of these studies (Table 3). The MMAS, the CHAMP, and the EMAS, provided a lot of data on the relationship between gonadal status and sexual desire, sexual function, and erectile function in middle-aged to older men (Table 3), suggesting that loss of sexual desire, but not erectile function, is strictly related to low T in aging men and could be predictive for the development of erectile dysfunction (ED). Thus, low serum T (the main component of low desire) is indirectly related to the onset of ED and to impaired male sexual function. In particular, in the EMAS study lower serum free T levels have been more strongly associated with severe sexual dysfunction (such as increased erectile dysfunction and lower masturbation frequency). Less data are available on sexual function in the BLSA and MrOS studies (Table 3).

Overweight and obesity are strongly associated to the decline of both serum T and SHBG in several studies such as the MMAS, the BLSA, the EMAS, and the Tromsö, showing an association between lower SHBG levels, but not T, and the development of metabolic syndrome. Metabolic syndrome was associated to low serum T and/or low SHBG in the BLSA, HIMS, InChianti, Tromsö, and RBS, showing that hypertension is associated to low serum T (Table 3). The EMAS study showed that weight loss is associated to an increase, while weight gain to a decrease in both total and free serum T, with the same association persisting by considering waist circumference. As previously reported, obesity probably determines an impairment of the hypothalamic-pituitary function, leading to lower LH incretion and finally to hypogonadotropic hypogonadism. This evidence is very important because it suggests that weight management and obesity avoidance could be useful to prevent T decline. Furthermore, the relationship between weight and T is probably bidirectional, since hypogonadism promotes fat accumulation and low total and free serum T levels have been associated with an increased risk of developing metabolic syndrome.

Data on the relationship between T and the cardiovascular (CV) system are available from the BLSA, the MrOS, the Tromsö, and the RBS, showing that hypertension is associated to low serum T (Table 3). As suggested by the Tromsø study, smoking, overweight, and obesity represent possible confounding factors when evaluating the relationship between serum T and CV diseases in cohort studies.

The major role of serum estrogens on bone health has been suggested by almost all the studies, serum E2 and T being directly correlated with bone mineral density (BMD). This correlation is particularly strong for free
serum E\textsubscript{2} \textsuperscript{86,118,119}. Furthermore, the MrOS has shown that low serum T together with high SHBG levels and low serum estradiol levels are associated with increased risk of non-vertebral fracture.\textsuperscript{117} On the other hand, data about the effects of serum T on BMD remain conflicting since the association between low serum T and lower BMD has not been demonstrated in all studies, such as the MrOS.\textsuperscript{120} In the EMAS study, however, men with overt hypogonadism (total T $<$ 230 ng/dL [8 nml/L]) show worse serum parameters of bone health compared with eugonadal men.\textsuperscript{118,121} Probably, T contributes to bone health through its effect on muscle mass (and the consequent mechanical load on bone) and via aromatization to estrogens.\textsuperscript{42,48,121} Thus, low circulating levels of T result in parallel in low serum E\textsubscript{2} and both BMD\textsubscript{71} and fracture risk.\textsuperscript{72} On the other hand, data on mood\textsuperscript{105} and cognition were also replicated by the MMAS,\textsuperscript{136} the CHAMP,\textsuperscript{137} and the MrOS.\textsuperscript{97}

In these large cohort studies, low serum free T was almost constantly associated with an increased all-causes mortality risk, this association was found by the HIMS,\textsuperscript{138} CHAMP,\textsuperscript{81} MMAS,\textsuperscript{139} EMAS,\textsuperscript{95} RBS,\textsuperscript{119} Tromso,\textsuperscript{140} and MrOS\textsuperscript{141} studies. In the MrOS the mortality risk appeared to be higher when also low serum E\textsubscript{2} was present.\textsuperscript{141} Vice versa, the InChianti study did not find any association between low baseline serum T levels and 6-years mortality risk.\textsuperscript{66} The association between low serum T and mortality due to CV events remains less known since this association was proven only by the HIMS study.\textsuperscript{138}

**Lesson learnt from large cohort studies**

The integrated analysis of data provided by these large longitudinal studies allows highlighting several issues that are of concern for research advancement, methodological outcome and finally for clinical practice.

At the beginning most of these longitudinal studies provided first analyses based on cross-sectional data.\textsuperscript{53,142} The longitudinal design of the studies came up progressively as the studies aged together with their participants. First cross-sectional data did not find changes in circulating sex steroids between older and younger participants.\textsuperscript{142} Subsequently, the decline of sex steroids was unequivocally proved when the data from longitudinal analyses became available. Accordingly, the most important result reached by all the studies is to demonstrate the serum T decline with advancing age. Particularly, both free and total serum T levels tend to decrease; the latter decreases lesser than the former as a consequence of the progressive increase of SHBG with aging (Table 4). Also the modification of SHBG has been confirmed by all the studies (Table 4).

In all studies that have investigated male sexuality, serum T resulted inversely related to sexual desire and to some extent to sexual activity and erectile function too (Table 4). Another concordant result is the association between low serum T and obesity, metabolic comorbidities such as the metabolic syndrome, and type 2 diabetes (Table 4).

Among other clinical aspects that are associated to serum T lowering with advancing age, all-cause mortality, body composition changes, especially overweight ad obesity as well as metabolic syndrome and diabetes, all have been over and over again associated to T decline in aging (Table 4).

The methodological approach used for T measurement has changed overtime according to advancements
in this field in all the studies (Table 4). At present, the gold standard LC-MS/MS is being used in all studies, while at the beginning of the studies sex steroids were measured by IAs. This implies that the comparison of the results coming from different studies as well as the results of the same study obtained in different periods by using different assay methods remain challenging. There is not consensus about the correlation between total serum T measured by MS and IAs among studies since some studies find a good correlation while others find discordant measurements (Table 4). This issue is important when data coming from research studies like these are transposed and applied to daily clinical practice since IAs are commonly employed, at present, in clinical laboratories.

A lesser degree of certainty has been reached regarding the association between T lowering with advancing age and CV diseases, increase in CV risk, ED, and impaired bone health (Table 4).

The most controversial issues concern the association of T decline to impaired physical performance, neuropsychological issues, CV-related mortality, and cancer risk (Table 4).

Table 4 summarizes in detail the main analogies and discrepancies regarding the issues that have been mostly investigated by large cohort studies till now (Table 4).

**Significance of age-related serum T changes in aging men**

The decline of serum T with advancing age has been traditionally interpreted as the male counterpart of menopause. In other words, the decrease of T was considered as a condition due to the aging of gonadal function. In this old view, the term andropause was considered as a physiological event like menopause in females\(^{143-145}\), with the unique difference that the ovaries stop to function suddenly while the testes loose their function gradually (Fig. 1).

At present, it has not defined whether the decline of serum T in the elderly represents a physiological process of aging or whether this event should be considered as pathological. In 2004 Snyder stated that ‘an essential but still unanswered question is whether this decrease in the testosterone concentration is physiologic, perhaps conveying a benefit, or pathologic, causing harm’\(^{146}\). Today, this point remains still crucial in order to establish if a strategy that is effective in counteracting serum T decline should be set up or if treating serum T decline maybe potentially harmful. With this in view, the identification of patients with low serum T that might benefit of replacement therapy on one hand and the recognition of those for which therapy is not indicated is challenging.

All these issues usually converge on the practical point concerning how to diagnose LOH\(^{147}\).

**The clinical diagnosis of LOH: lights and shadows**

Recently, there is consensus among endocrinologists, andrologists, and urologists about the fact that the finding of biochemical T deficiency does not necessarily correspond to LOH in middle-aged-to-older men.\(^ {12,25,38-40,49,147,148}\) Accordingly, lower serum T in older men should not be considered ‘per se’ significant, but it acquires a clinical value in men with concomitant signs and symptoms of T deficiency, a condition known as hypogonadism.\(^ {3,12,25,38,40,49,148}\) Some aspects related to the diagnosis of hypogonadism do not differ according to the patients’ age (e.g., categories of hypogonadism), while for other aspects (e.g., causes of hypogonadism, signs and symptoms, and serum T thresholds) the patients’ age does matter.\(^ {40,49,149,150}\)

**Classification of LOH**

In general, 2 main forms of hypogonadism can be distinguished: (a) primary hypogonadism (or hypergonadotropic hypogonadism), where the site of origin is the testis and which is characterized by low T levels with high gonadotropins levels, and (b) secondary hypogonadism (or hypogonadotropic hypogonadism), in which there is hypothalamic and/or pituitary failure causing low gonadotropins production and consequent low T levels\(^ {12,25,49,148}\) (Fig. 2). Furthermore, among aging men is quite common a condition of compensated hypogonadism, represented by normal T levels with high gonadotropins levels, whose prevalence increases with aging and which seems to be a subclinical condition that could develop in overt, primary hypogonadism (Fig. 2). Recently, data coming from the EMAS study confirm that age is correlated with the development of primary hypogonadism, but not with secondary hypogonadism, the latter being strictly associated to comorbidities rather than age.\(^ {3,151,152}\)

**Causes of LOH**

In younger men hypogonadism (both hypergonadotropic and hypogonadotropic) is usually due to well-known causes, which can be congenital or acquired, and the site of origin is easily recognizable.\(^ {40,49,149,150}\) Conversely, many different factors, some of which are still not well defined, contribute to the decrease of T production in aging men (Table 1). For example, aging ‘per se’ is known to induce a progressive dysfunction of Leydig cells, but age-advanced typical chronic comorbidities (e.g., cancer, chronic obstructive pulmonary disease, chronic renal failure and chronic liver failure) are also associated with low serum T (Table 1).\(^ {6,153}\) Accordingly, age and chronic diseases resulted associated to primary
hypogonadism in the EMAS cohort.\textsuperscript{151} Thus, low serum T of the elderly man is often due to both primary and secondary failure of T secretion. Other factors involved in serum T declining include bad lifestyle habits, such as smoking and excessive alcohol intake, and chronic therapies with opiates and glucocorticoids, increasingly used to treat elderly population (Table 1).\textsuperscript{6} Several clinical conditions (e.g., chronic or acute diseases) are associated to hypogonadism in aging men, some of them cause secondary hypogonadism, which is not related to age and might be reversible.\textsuperscript{15,152} In particular, diabetes mellitus, obesity and metabolic syndrome seem to play a major role especially in decreasing gonadotropin levels, leading to secondary hypogonadism, which is not related to age and might be reversible.\textsuperscript{15,152} Chronic liver diseases, especially cirrhosis and fatty liver disease,\textsuperscript{155} are associated to hypogonadism as a consequence of increased liver production of SHBG and of estrogen excess and its inhibitory effect on gonadotropins.\textsuperscript{22}

The prevalence of hypogonadism seems to be high in men with chronic obstructive pulmonary disease (COPD), especially in middle-aged and elderly men,\textsuperscript{22,153} ranging from 22 to 69%.\textsuperscript{156,157} In particular, secondary hypogonadism is associated to COPD and the severity of COPD seems to be directly correlated with the degree of hypogonadism.\textsuperscript{157} An interesting, not widely investigated association has been found between low total and free serum T levels and impaired pulmonary function evaluated by spirometry in the Tromsø study.\textsuperscript{116} Considering that oxygen therapy is known to increase T levels in men with respiratory failure, it seems more likely that poor, pulmonary function is responsible of lower T levels and not vice-versa, may be by altering the hypothalamic-
pituatary function. The studies on COPD, however, are scanty and have been performed on small samples of patients, thus more data from more studies are still needed to better characterize hypogonadism in older men with COPD.22

Male hypogonadism is highly prevalent also in patients with chronic kidney disease as a consequence of testicular damage (primary hypogonadism).21,22,159 In patients who undergo hemodialysis for the first time hypogonadism do not normalize and tends to worsen, only renal transplantation being able to restore normal serum T21,22,159,160.

Several congenital systemic diseases might induce hypogonadism in the young, adult man and hypogonadism is intended to worsen with advancing age as in the case of β-thalassemia161 and hemocromatosis.162

Finally, treatments used for systemic chronic diseases might induce hypogonadism as in the case of rheumatoid arthritis.22,153 or treatment for cancer22.

The issue concerning the relationship existing between morbidities and LOH is relevant since might to be bidirectional.40 On one hand, LOH sustains or exacerbates morbidities, while, on the other hand, LOH might be caused by comorbidities and might be reversible if comorbidities are treated.40 The same hormonal change occurs in patients with other acute illnesses different from infectious diseases.163-165 These changes seem to be part of a mechanism, which is adaptive to poor health status aiming to counteract the high catabolic state due to the acute, severe clinical condition. By decreasing the activity of the pituitary-gonadal axis it is possible to reduce some body functions (e.g., physical and sexual activity), thus allowing sparing energy and avoiding reproduction during a unhealthy condition.165 Since chronic diseases are associated to hypogonadism in the male,153,163 it has been postulated that in a part of men developing T deficiency with advancing age LOH maybe the consequence of multimorbidity that accumulates in the aging patient.40 With this in view, a considerable quote of LOH are not consistent with a clinical condition of hypogonadotropic hypogonadism.169,170 (Fig. 2). The same hormonal change occurs in patients with other acute illnesses different from infectious diseases.163-165 These changes seem to be part of a mechanism, which is adaptive to poor health status aiming to counteract the high catabolic state due to the acute, severe clinical condition. By decreasing the activity of the pituitary-gonadal axis it is possible to reduce some body functions (e.g., physical and sexual activity), thus allowing sparing energy and avoiding reproduction during a unhealthy condition.165 Since chronic diseases are associated to hypogonadism in the male,153,163 it has been postulated that in a part of men developing T deficiency with advancing age LOH maybe the consequence of multimorbidity that accumulates in the aging patient.40 With this in view, a considerable quote of LOH are the severity of patients’s clinical condition,163,168 and might be transitory and reversible.167,171 This mechanism based on a strict relationship between patient’s poor health status and low serum T operates especially in aging men and share a mechanism involving the hypothalamus and the pituitary resulting in secondary hypogonadism.5,9,100,152

Aging, hypogonadism, and frailty. As mentioned above, patient’s poor health status in terms of deteriorated clinical conditions might influence T secretion. In aging men, however, the more complicated, multidimensional concept named frailty should be also considered.172 Frailty depends not only by the clinical condition of the patients, but encompasses also all the physiological and pathological changes accumulating during aging that impair patients’ physical performance (e.g., sarcopenia, osteoporosis, walking disabilities, impairment of visual acuity) as well as his psychological status (loss of memory, depressed mood) and well-being.172-174 All these factors contribute to frailty and expose the aging man to experiment harmful events (e.g., falls, progressive reduction of physical activities).172-174

Frailty is inversely related to serum T in older men, as substantiated by several studies.15,17,154,175-177 Furthermore, sarcopenia is directly related to low serum T178 and takes part to the physiological process of aging itself.179-181 Even chronic illnesses are able to induce sarcopenia.180,182 Thus it is evident that sarcopenia should be considered as a central player in the relationships among LOH, frailty, and comorbidities.181

Aging, hypogonadism, and infectious diseases. Data available on the relationship among aging, hypogonadism, and infectious diseases are scanty. It is well known that sepsis induces a fall of serum T in men together with a decrease of serum LH, consisting with a condition of hypogonadotropic hypogonadism.169,170 (Fig. 2). The same hormonal change occurs in patients with other acute illnesses different from infectious diseases.163-165

These changes seem to be part of a mechanism, which is adaptive to poor health status aiming to counteract the high catabolic state due to the acute, severe clinical condition. By decreasing the activity of the pituitary-gonadal axis it is possible to reduce some body functions (e.g., physical and sexual activity), thus allowing sparing energy and avoiding reproduction during a unhealthy condition.165 Since chronic diseases are associated to hypogonadism in the male,153,163 it has been postulated in a part of men developing T deficiency with advancing age LOH maybe the consequence of multimorbidity that accumulates in the aging patient.40 With this in view, a considerable quote of LOH are

Acute non-infectious diseases. Serum T might fall down in patients with acute, critical illnesses and normal serum T levels are restored by the resolution of the acute clinical condition.164,167,168 This condition occurs regardless the nature of the acute illness,163,164,169,170 it is associated to
not consistent with a clinical condition of hypogonadism, but represents an epiphenomenon of a poor health status, which is a common condition in the elderly.38,40

Among infectious diseases that may interfere with circulating T, rare testicular infections causing orchitis usually induce a temporary or permanent primary hypogonadism (hypergonadotropic hypogonadism).183 Conversely, chronic viral hepatitis are often related to an increase of serum total T rather to T deficiency; this condition is due to the rise of SHBG and does not modify free serum T.184

**Hypogonadism and HIV infection.** Among HIV infected-men a process of accelerated aging seems to take place, deriving from a multifactorial etiology (immunosenescence, inflammation, multimorbidity); therefore, HIV infection can be considered a model of premature aging.185 Accordingly, a premature decline of serum T has been described in this population.186 The prevalence of biochemical hypogonadism in HIV-infected men is around 25% in young-to-middle-aged men50 and serum T decline in HIV-infected men aged 45–60 y seems to parallel what happens in older men after 60.50,186 In HIV-infected patients secondary hypogonadism is more common and is associated to fat redistribution and visceral adiposity.50,186 Furthermore, low levels of serum T are associated with to higher number of comorbidities and are inversely related to frailty.166 The latter finding does not help in establishing if these patients are truly hypogonadic or if their low T is related only to their poor health status.

The diagnosis of hypogonadism in these patients shares all the problems physicians have with older men and it is even more difficult due to the fact that symptoms and signs are much more less specific than in the general population. Sign and symptoms, especially those related to sexuality and body composition changes, overlap, in fact, with those of HIV infection.50

Finally, SHBG measurements is mandatory in men with HIV since SHBG alterations are very common in these patients and might lead to underestimation of hypogonadism.50

**Serum T thresholds for LOH diagnosis.** The cut-off of serum total T below which the diagnosis of overt biochemical hypogonadism could be formulated remains to be determined. Different studies,3,187,188 clinical guidelines12,25,33,148,154 (https://uroweb.org/guideline/male-hypogonadism/), expert panels,49 and extensive literature revision,38,40,147 provided different cutoffs. However, all the cutoffs fall within the interval of serum total T comprised between 180 ng/dL and 300 ng/dL (Table 5).

Since T secretion follows a circadian rhythm, with peak values in the morning, T measurement should be performed in the morning, preferably in 2 different occasions12,25,33,38,49,148,154 (https://uroweb.org/guideline/male-hypogonadism/). When serum total T levels are borderline evaluation of free T can be useful, especially among older men who physiologically tend to have increased levels of SHBG33,154. In particular, SHBG measurement is indicated in obese patients and patients with chronic diseases (e.g., HIV-infection, viral hepatitis).25

### Table 5. Serum testosterone (T) cutoffs suggested for the diagnosis of LOH.

| Cutoff Provider                  | Biochemical Hypogonadism | Gray Area (Mild Biochemical Hypogonadism) | Normal T |
|---------------------------------|--------------------------|------------------------------------------|----------|
| Endocrine Society Guidelines    | <300 (<10.4)             | –                                        | >300 (>10.4) |
| AACE Guidelines                 | 202 (<7)                 | –                                        | >202 (>7) |
| ISA, ISSAM, EAU, EAA, & ASA Guidelines | <231 (<8)               | 231 < T < 346 (8 < T < 12.0)            | >346 (>12.0) |
| EMAS Study (<5th percentile)    | <185 (<6.4)              | –                                        | >185 (>6.4) |
| HIMS Study (<5th percentile)    | <185 (<6.4)              | –                                        | >185 (>6.4) |
| MMAS Study 40–49 yrs             | <251 (<8.7)              | –                                        | >251 (>8.7) |
| MMAS Study 50–59 yrs             | <216 (<7.5)              | –                                        | >216 (>7.5) |
| MMAS Study 60–69 yrs             | <196 (<6.8)              | –                                        | >196 (>6.8) |
| MMAS Study >70 yrs               | <156 (<5.4)              | –                                        | >156 (>5.4) |
| Australian Clinical Pathology Laboratories | <185 (<6.4)          | –                                        | >185 (>6.4) |
| ISA, ISSAM, EAU, EAA, & ASA Guidelines | <64.8 (<225)         | –                                        | >64.8 (>225) |
| EMAS Study                      | <63.4 (<220)             | –                                        | >63.4 (>220) |

[https://uroweb.org/guideline/male-hypogonadism/](https://uroweb.org/guideline/male-hypogonadism/)

Notes. T: testosterone; AACE: American Association of Clinical Endocrinologists; ISA: International Society of Andrology; ISSAM: International Society for the Study of the Aging Male; EAU: European Association of Urology; EAA: European Academy of Andrology; ASA: American Society of Andrology; EMAS: The European Male Aging Study; MMAS: The Massachusetts Male Aging Study.
It is important to remark, however, that common laboratory assays used for free T measurement are not reliable and calculation of free T starting from total T, albumin and SHBG with equations that have been validated should be preferred. Some guidelines or large longitudinal studies have provided thresholds also for calculated serum free T (http://www.issam.ch/freetesto.htm) (Table 5).

**Signs and symptoms of hypogonadism.** The diagnosis of hypogonadism requires both biochemical measurements and clinical features (https://uroweb.org/guideline/male-hypogonadism/). Since very often the symptoms suggestive of low T are attributed to age among older men, recognizing hypogonadism is not easy. The interview is essential in order to disclose symptoms of hypogonadism, which belong mainly to sexual and physical functions. The most specific symptoms related to the decrease of serum T are: reduced sexual desire (libido) and activity, decreased spontaneous erections in the morning, erectile dysfunction, reduced shaving frequency, decreased energy and vitality, and occasionally hot flushes (Fig. 3). Other symptoms are less specific (e.g., depressed mood and reduced muscle strength) (Fig. 3).

At physical examination, signs suggestive of hypogonadism should be investigated, such as reduced pubic and axillary hair, reduced testicular size and volume of ejaculation. Figure 3 summarizes sign of hypogonadism according with their specificity. In conclusion, the best way for the diagnosis is to combine serum T (total or free) with the symptoms, regarding at LH as an adjunctive information useful to obtain a comprehensive picture of the pituitary gonadal axis and to find patients at higher risk to develop hypogonadism in the next future (compensated hypogonadism) (Figure 2).

**Other examinations.** If low serum total T is confirmed, measurement of serum LH and follicle-stimulating hormone (FSH) is recommended in order to identify primary or secondary hypogonadism (Figure 2). Both the conditions can be found in older men without specific endocrinological causes, nonetheless when LH and FSH levels are very low and suggest a central origin of hypogonadism, a global evaluation of pituitary function should be taken to exclude hypopituitarism.

---

**Figure 3.** Signs and symptoms of late-onset hypogonadism according to their specificity.
Finally, bone densitometry should be performed in case of low T, because hypogonadism often is responsible for osteopenia, osteoporosis, and increased fracture risk in older men.48

**Testosterone replacement treatment: Certain knowledge and controversies**

Since many factors involved in low T onset are reversible, life-style modifications, such as smoke abolition and moderate alcohol consumption, physical activity and weight loss should be suggested not only to avoid hypogonadism, but also for general well-being in older age.147 Similarly, the resolution of acute illnesses40,164,165 or the improvement of chronic diseases that might cause hypogonadism152 generally improve serum T as well as clinical condition in older men.171

Patients who are candidate to receive T replacement are those with documented LOH, concomitant symptoms and/or signs of low T (especially sexual symptoms) and no contraindication to T treatment.12,25,33,38,49,148,154 Treatment should be tailored according to patient’s health status and expectations after having considered the potential risk and after having informed the patients about possible risk and benefits.12,25,33,38,49,148,154 Evidence coming from randomized trials in men older than 60 y is, in fact, still lacking and future large, prospective studies are required and worthwhile.189

At present, there is consensus against T treatment in men with a serum total T above 346 ng/dL (12 nmol/L).12,38,49,154 or values of serum T very close to 346 ng/dL (https://uroweb.org/guideline/male-hypogonadism/).

T treatment is effective in improving sexual function, but this effect is not evident in men with normal serum T.190 Other beneficial effects are related to the improvement of body composition and metabolic outcome.40

It has been supposed that T treatment might increase CV risk (http://www.fda.gov/Drugs/DrugSafety/ucm436259.htm) on the basis of CV events reported in some of the T trials.189,191-194 However, at present 4 different meta-analyses have not found this association to be consistent194-197 while only one confirmed an increased CV risk due to T treatment.198

Contraindications are documented prostate and breast cancer, and strong caution should be used when hematocrit is increased (>50%).12,25,33,38,49,148,154 Other aspects that should be considered are congestive heart failure, sleep apnea, benign prostatic hyperplasia and a prostate specific antigen (PSA) >4 ng/mL.12,25,33,38,49,148,154 Furthermore, patients with a recent (within 6 months) history of CV events should not be considered as candidate to receive T replacement treatment.38,40,49,189

The patient should be informed about potential benefits that involve mainly sexual desire and function, vigor, body composition changes and prevention of bone loss. At the same time, patient should be aware that T treatment in older men might be harmful and that evidence in favor of its safety is not of good quality.

**Unresolved issues**

Sexual symptoms are the most useful to prompt the diagnosis of LOH, but they are also difficult to unmask in the consistent percentage of patients (especially older men) who are reluctant to talk about them with physicians.199 In addition, even physicians are less prone to interview aging men about their sexuality.200

We know that among men with a diagnosis of LOH there are false positive and that this diagnosis is probably overlooked in other men (false negative). However, it is very difficult to have precise data concerning the accuracy of LOH diagnosis due to the lack of certain diagnostic criteria. Concerning the diagnosis of LOH, there is still a gap of knowledge about the significance of great serum T decrease from the baseline overtime (e.g., 50%) leading to a serum value still in the range of eugonadism, but much lower than in the past. It is possible that patients with this kind of serum T decline trajectory become truly hypogonadal and already display sign and symptoms of hypogonadism.38 Furthermore, data on the natural history of LOH are scanty.171

From literature we know that LOH might be reversible in about half of the patients,171 but at present we are not able to predict, among patients with LOH, who will return to normal androgenization, except for those patients who are obese or overweight and loose weight.147

In the field of geriatrics is getting growing importance the concept of frailty, which is defined as a condition of vulnerability to stressing events. The condition of frailty derives from accumulation of deficits in multiple physiological systems and can be quantified by a frailty index. At present, the impact of T decline on frailty remains to be determined. Accordingly, it is not clear if T treatment is able to improve or worsen frailty in older men. Similarly, the potential for T treatment to be harmful in sick older men or in men with HIV infection and a poor health status remains an unsolved issue.189

At present, no association between serum T and life expectancy was found by comparing long-lived with short-lived subjects.201 However, differences in lifespan between men and women suggest a putative role of sex hormones on longevity.202 What we know is that lifespan was not different between singers castrated before puberty and non-castrated singers, suggesting that T does not influence longevity.203
probably might protect centrally from the effects of stress by mitigating the central cascade of events induced by the exposure to stress, while women are more exposed the negative effect of stress. How much gender differences in the exposure to sex steroids at any age are involved in determining longevity and the response to stress remains to be established in detail.

Conclusions

The decline of sex steroids with advancing age depends on gender and interindividual differences. In men physiological changes should be differentiated from pathological low serum T and the coupling low serum T with hypogonadism-related signs and symptoms is a good strategy to diagnose LOH and to identify patients who might benefit from T replacement. However, the specificity of symptoms of hypogonadism is low and measurements of serum T insidious, thus all these factors increase the risk of misdiagnosis. The presence/absence of concomitant acute or chronic illnesses could lead the physician avoiding misdiagnosis and overtreatment. Patients’ health status, in fact, should be taken into account prior to start T treatment to prevent adverse events that are more common in men with poor clinical conditions. Replacement treatment might be effective in improving sexual function, body composition, metabolic outcome, and vitality. In older men T treatment is not based on good evidence and the patient should be informed about the lack of proven beneficial effects as well as on the possible side effects and adverse events.

Abbreviations

AACE American Association of Clinical Endocrinologists
ASA American Society of Andrology
BLSA The Baltimore Longitudinal Study of Aging
BMD bone mineral density
BMI body mass index
CHAMP The Concorde Health and Aging in Men Project
COPD chronic obstructive pulmonary disease
CV cardiovascular
E2 estradiol
EAA European Academy of Andrology
EAU European Association of Urology
ED erectile dysfunction
EMAS European Male Aging Study
F females
FSH follicle-stimulating hormone
fT free testosterone
GH growth hormone
GnRH gonadotropin-releasing hormone
HIMS The Health in Men Study
HIV Human Immunodeficiency Virus
IAs Immunoassays
IGF-1 insulin-like growth factor-1
ISA International Society of Andrology
ISSAM International Society for the Study of the Aging Male
LC-MS/MS liquid chromatography-tandem mass spectrometry
LH luteinizing hormone
LOH late-onset hypogonadism
M males
MC-PLOC-B MultiCenter, Prospective, Longitudinal, Observational, Community-Based Study
MMAS The Massachusetts Male Aging Study
MrOS The Osteoporotic Fractures in men Study
MS mass spectrometry
n.a. not available
P-BRT Population-Based, Randomized, Trial
PLOC-B Prospective, Longitudinal, Observational, Community-Based Study
PSA prostate specific antigen
RBS The Rancho Bernardo Study
SHBG sex-hormone binding globuline
T testosterone
TSH thyrotropin hormone
TT total testosterone
US ultrasonography.

Disclosure of potential conflicts of interest

No potential conflicts of interest were disclosed.

Acknowledgments

The authors thank Prof. Paola Ugolini, Department of Romance Languages, SUNY Buffalo, NY, USA for having proofread the manuscript.

ORCID

Vincenzo Rochira http://orcid.org/0000-0001-8169-0696

References

[1] Veldhuis JD. Changes in pituitary function with ageing and implications for patient care. Nat Rev Endocrinol 2013; 9:205-15; PMID:23438832; https://doi.org/10.1038/nrendo.2013.38
[2] Al-Safi Z, Santoro N. The Postmenopausal Woman. In: De Groot LJ, Beck-Peccoz P, Chrousos G, Dungan K,
Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999; 84:3666-72; https://doi.org/10.1210/jcem.84.10.6079

Ly LP, Sartorius G, Hull L, Leung A, Swerdlow RS, Wang C, Handelsman DJ. Accuracy of calculated free testosterone formulae in men. Clin Endocrinol 2010; 73:382-8; https://doi.org/10.1111/j.1365-2265.2010.03804.x

Travison TG, Araujo AB, Kupelian V, O’Donnell AB, McKinlay JB. The relative contributions of aging, health, and lifestyle factors to serum testosterone decline in men. J Clin Endocrinol Metab 2007; 92:549-55; https://doi.org/10.1210/jc.2006-1859

Lapauw B, Goemaere S, Zmierczak H, Van Poppelbergh I, Mahmoud A, Taes Y, De Bacquer D, Vansteelandt S, Kaufman JM. The decline of serum testosterone levels in community-dwelling men over 70 years of age: descriptive data and predictors of longitudinal changes. Eur J Endocrinol/Eur Federat Endocrine Soc 2008; 159:459-68; https://doi.org/10.1530/EJE-07-0873

Tajar A, O’Connell MD, Mitnitski AB, O’Neill TW, Searle SD, Huhtaniemi IT, Finn JD, Bartfai G, Boonen S, Casanueva FF, et al. Frailty in relation to variations in hormone levels of the hypothalamic-pituitary-testicular axis in older men: results from the European male aging study. J Am Geriatrics Soc 2011; 59:814-21; https://doi.org/10.1111/j.1532-5415.2011.03398.x

Antonio L, Wu FC, O’Neill TW, Pye SR, Carter EL, Finn JD, Rutter MK, Laurent MR, Huhtaniemi IT, Han TS, et al. Associations between sex steroids and the development of metabolic syndrome: a longitudinal study in European men. J Clin Endocrinol Metab 2015; 100:1396-404; https://doi.org/10.1210/jc.2014-0388

Brand JS, Rovers MM, Yeap BB, Schneider HJ, Tuomainen TP, Haring R, Corona G, Onat A, Maggio M, Bouchard C, et al. Testosterone, sex hormone-binding globulin and the metabolic syndrome in men: an individual participant data meta-analysis of observational studies. PloS One 2014; 9:e100409; PMID:25019163; https://doi.org/10.1371/journal.pone.0100409

Corona G, Rastrelli G, Monami M, Saad F, Luconi M, Lucchese M, Facchiano E, Sforza A, Forti G, Mannucci E, et al. Body weight loss reverts obesity-associated hypogonadotropic hypogonadism: a systematic review and meta-analysis. Eur J Endocrinol/Euro Federat Endocrine Soc 2013; 168:829-43; https://doi.org/10.1530/EJE-12-0955

Palmer BF, Clegg DJ. Gonadal dysfunction in chronic kidney disease. Rev Endoc Metab Dis 2016.

Karagiannis A, Harsoulis F. Gonadal dysfunction in systemic diseases. Eur J Endocrinol/Euro Federat Endocrine Soc 2005; 152:501-41; https://doi.org/10.1530/EJE-07-0955

Winters SJ. Laboratory Assessment of Testicular Function. In: De Groot LJ, Beck-Peccoz P, Chrousos G,
Dungan K, Grossman A, Hershman JM, Koch C, McLachlan R, New M, Rebar R, et al., eds. Endotext. South Dartmouth MA: MDText.com, Inc., 2000.

Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdlow RS, Montori VM. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010; 95:2536-59; https://doi.org/10.1210/jc.2009-2354

Wang Y, Gay GD, Botelho JC, Caudill SP, Vesper HW. Total testosterone quantitative measurement in serum by LC-MS/MS. Clinica Chimica Acta; Int J Clin Chem 2014; 436:263-7; PMID:24960363; https://doi.org/10.1016/j.cca.2014.06.009

Wang C, Catlin DH, Demers LM, Starcevic B, Swerdlow RS. Measurement of total serum testosterone in adult men: comparison of current laboratory methods versus liquid chromatography-tandem mass spectrometry. J Clin Endocrinol Metabol 2004; 89:534-43; https://doi.org/10.1210/jc.2003-031287

Fanelli F, Belluomo I, Di Lallo VD, Cuomo G, De Iasio R, Baccini M, Casadio E, Casetta B, Vicennati V, Gambineri A, et al. Serum steroid profiling by isotopic dilution-liquid chromatography-mass spectrometry: comparison with current immunoassays and reference intervals in healthy adults. Steroids 2011; 76:244-53; PMID:21112348; https://doi.org/10.1016/j.steroids.2010.11.005

Rosner W, Auchus RJ, Azziz R, Sluss PM, Raff H. Position statement: utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement. J Clin Endocrinol Metabol 2007; 92:405-13; https://doi.org/10.1210/jc.2006-1864

Rosner W, Vesper H. Toward excellence in testosterone testing: a consensus statement. J Clin Endocrinol Metabol 2010; 95:4542-8; https://doi.org/10.1210/jc.2010-1314

Ketha H, Kaur S, Grebe SK, Singh RJ. Clinical applications of LC-MS sex steroid assays: evolution of methodologies in the 21st century. Curr Opin Endocrinol, Diab Obes 2014; 21:217-26; PMID:24739314; https://doi.org/10.1097/MED.0000000000000686

Huthaniemi IT, Tajar A, Lee DM, O'Neill TW, Finn JD, Bartfai G, Boonen S, Casanueva FF, Giwercman A, Han TS, et al. Comparison of serum testosterone and estradiol measurements in 3174 European men using platform immunoassay and mass spectrometry; relevance for the diagnostics in aging men. Euro J Endocrinol/ Euro Federat Endocrine Soc 2012; 166:983-91; https://doi.org/10.1530/EJE-11-1051

Morales A, Bebb RA, Manjoo P, Assimakopoulos P, Axler J, Collier C, Elliott S, Goldenberg L, Gottesman I, Grober ED, et al. Diagnosis and management of testosterone deficiency syndrome in men: clinical practice guideline. CMAJ: Canadian Med Assoc J = J de l’Assoc Med Canadienne 2015; 187:1369-77; PMID:26504097; https://doi.org/10.1503/cmaj.150033

Bremner WJ, Vitiello MV, Prinz PN. Loss of circadian rhythmicity in blood testosterone levels with aging in normal men. J Clin Endocrinol Metabol 1983; 56:1278-81; https://doi.org/10.1210/jcem-56-6-1278

Brambilla DJ, O’Donnell AB, Matsumoto AM, McKinlay JB. Intraindividual variation in levels of serum testosterone and other reproductive and adrenal hormones in men. Clin Endocrinol 2007; 67:853-62; PMID:18052942; https://doi.org/10.1111/j.1365-2265.2007.02976.x

Gonzalez-Sales M, Barriere O, Tremblay PO, Neeka F, Desrochers J, Tanguay M. Modeling testosterone circannual rhythm in hypogonadal males: effect of age and circannual variations. AAPS J 2016; 18:217-27; PMID:26553482; https://doi.org/10.1208/s12248-015-9841-6

Feldman HA, Longcope C, Derby CA, Johannes CB, Araujo AB, Coviello AD, Bremner WJ, McKinlay JB. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metabol 2002; 87:589-98; https://doi.org/10.1210/jcem.87.2.8201

Huthaniemi I. Late-onset hypogonadism: current concepts and controversies of pathogenesis, diagnosis and treatment. Asian J Androl 2014; 16:192-202; PMID:24407185; https://doi.org/10.4103/1008-682X.122336

Corona G, Rastrelli G, Vignozzi L, Mannucci E, Maggi M. How to recognize late-onset hypogonadism in men with sexual dysfunction. Asian J Androl 2012; 14:251-9; PMID:22286862; https://doi.org/10.1038/aja.2011.138

Corona G, Maseroli E, Rastrelli G, Francomano D, Avessa A, Hackett G, Ferri S, Sforza A, Maggi M. Is late-onset hypogonadotrophic hypogonadism a specific age-dependent disease, or merely an epiphenomenon caused by accumulating disease-burden? Focusing on metabolic diseases. Minerva Endocrinol 2016; PMID:26883937

Rodriguez A, Muller DC, Metter EJ, Maggio M, Harman SM, Blackman MR, Andres R. Aging, androgens, and the metabolic syndrome in a longitudinal study of aging. J Clin Endocrinol Metabol 2007; 92:3568-72; https://doi.org/10.1210/jc.2006-2764

Rochoira V, Kara E, Carani C. The endocrine role of estrogens on human male skeleton. Int J Endocrinol 2015; 2015:165215; PMID:25873947; https://doi.org/10.1155/2015/165215

Mellstrom D, Vandenput L, Mallmin H, Holmberg AH, Lorentzon M, Oden A, Johannson H, Orwoll ES, Labrie F, Karlsson MK, et al. Older men with low serum estradiol and high serum SHBG have an increased risk of fractures. J Bone Mineral Res: Off J Am Soc Bone Min Res 2008; 23:1552-60; PMID:18518773; https://doi.org/10.1359/jbmr.080518

Rochoira V, Zirilli L, Genazzani AD, Ballestriera A, Aranda C, Fabre B, Antunez P, Dizzi C, Carani C, Maffeil E. Hypothalamic-pituitary-gonadal axis in two men with aromatase deficiency: evidence that circulating estrogens are required at the hypothalamic level for the integrity of gonadotropin negative feedback. Euro J Endocrinol/ Eur Federat Endocrine Soc 2006; 155:513-22; https://doi.org/10.1530/eje.1.02254

Finkelstein JS, Lee H, Burnett-Bowie SA, Pallais JC, Yu EW, Borges LF, Jones BF, Barry CV, Wulczyn KE,
[46] Carani C, Rochira V, Faustini-Fustini M, Balestrieri A, Granata AR. Role of oestrogen in male sexual behaviour: insights from the natural model of aromatase deficiency. Clin Endocrinol 1999; 51:517-24; PMID:10583321; https://doi.org/10.1046/j.1365-2265.1999.00849.x

[47] Cunningham GR, Stephens-Shields AJ, Rosen RC, Wang C, Ellenberg SS, Matsumoto AM, Bhasin S, Moltitch ME, Farrar JT, Cella D, et al. Association of sex hormones with sexual function, vitality, and physical function of symptomatic older men with low testosterone levels at baseline in the testosterone trials. J Clin Endocrinol Metabol 2015; 100:1146-55; https://doi.org/10.1210/jc.2014-3818

[48] Rochira V, Balestrieri A, Madeo B, Zirilli L, Granata AR. Role of oestrogen in male sexual behaviour: the Tromso Study. JBone Miner Metab: Off J Soc Bone Miner Res 2004; 22:265-69; PMID:15638872; https://doi.org/10.1016/j.bone.2004.02.017

[49] Lee DM, Pye SR, Tajar A, O’Neill TW, Finn JD, Pendleton N, Tajar A, Bartfi G, Casanueva F, Forti G, et al. The European Male Ageing Study (EMAS): design, methods and recruitment. Int J Androl 2009; 32:11-24; PMID:18328041; https://doi.org/10.1111/j.1365-2605.2008.00879.x

[50] Gray A, Feldman HA, McKinlay JB, Longcope C. Age, disease, and changing sex hormone levels in middle-aged men: results of the Massachusetts Male Aging Study. J. Clin. Endocrinol. Metab. 1991; 73:1016-25; https://doi.org/10.1210/jcem-73-5-1016

[51] Deslypere JP, Vermeulen A. Leydig cell function in normal men: effect of age, life-style, residence, diet, and activity. J Clin Endocrinol Metabol 1984; 59:955-62; https://doi.org/10.1210/jcem-59-5-955

[52] Baker HW, Burger HG, de Kreter DM, Hudson B, O’Connor S, Wang C, Mirovics A, Court J, Dunlop M, Rennie GC. Changes in the pituitary-testicular system with age. Clin Endocrinol 1976; 5:349-72; PMID:971543; https://doi.org/10.1111/j.1365-2265.1976.tb01964.x

[53] Desire JR, Valsecchi F, Vermeulen A, Leydig cell function in normal men: effect of age, life-style, residence, diet, and activity. J Clin Endocrinol Metabol 1984; 59:955-62; https://doi.org/10.1210/jcem-59-5-955

[54] Baker HW, Burger HG, de Kreter DM, Hudson B, O’Connor S, Wang C, Mirovics A, Court J, Dunlop M, Rennie GC. Changes in the pituitary-testicular system with age. Clin Endocrinol 1976; 5:349-72; PMID:971543; https://doi.org/10.1111/j.1365-2265.1976.tb01964.x

[55] Seftel AD. Male hypogonadism. Part I: epidemiology of hypogonadism. Int J Impot Res 2006; 18:115-20.

[56] Orwoll E, Blank JB, Barrett-Connor E, Cauley J, Pendleton N, Tajar A, Bartfi G, Casanueva F, Forti G, et al. The European Male Ageing Study (EMAS): design and baseline characteristics of the osteoporotic fractures in men (MrOS) study—a large observational study of the determinants of fracture in older men. Contemp Clin Trials 2005; 26:569-85; PMID:16084776; https://doi.org/10.1016/j.cct.2005.05.006

[57] Lee DM, O’Neill TW, Pye SR, Silva AN, Finn JD, Pendleton N, Tajar A, Bartfi G, Casanueva F, Forti G, et al. The European Male Ageing Study (EMAS): design, methods and recruitment. Int J Androl 2009; 32:11-24; PMID:18328041; https://doi.org/10.1111/j.1365-2605.2008.00879.x

[58] Lee DM, Pye SR, Tajar A, O’Neill TW, Finn JD, Boonen S, Bartfi G, Casanueva FF, Forti G, Giwercman A, et al. Cohort profile: the European male ageing study. Int J Epidemiol 2013; 42:391-401; PMID:22314965; https://doi.org/10.1093/ije/dyr234

[59] Barrett-Connor E. The Rancho Bernardo Study: 40 years studying why women have less heart disease than men and how diabetes modifies women’s usual cardiac protection. Global heart 2013; 8; PMID:24187655; https://doi.org/10.1016/j.gheart.2012.12.002

[60] Maggio M, Lauretani F, Ceda GP, Bandinelli S, Basaria S, Bartfi G, Casanueva FF, Forti G, Giwercman A, et al. Relationship between low levels of anabolic hormones and 6-year mortality in older men: the aging in the Chianti Area (InCHIANTI) study. Arch Int Med 2007; 167:2249-54; PMID:17998499; https://doi.org/10.1001/archinte.167.20.2249

[61] Maccio M, Lauretani F, Ceda GP, Bandinelli S, Basaria S, Paolisso G, Giemelli C, Luci M, Najar SS, Metter EJ, et al. Estradiol and metabolic syndrome in older Italian men: the InCHIANTI Study. J Androl 2010; 31:155-62; PMID:19059904; https://doi.org/10.2164/jandrol.108.006098

[62] Stone JL, Norris AH. Activities and attitudes of participants in the Baltimore longitudinal study. J Gerontol 1966; 21:575-80; PMID:5918312; https://doi.org/10.1093/geronji/21.4.575
associations with 4.5-year change in hip bone mineral density—the osteoporotic fractures in men study. J Clin Endocrinol Metabol 2010; 95:4314-23; https://doi.org/10.1210/jc.2009-2635

[88] Cawthon PM, Schousboe JT, Harrison SL, Ensrud KE, Black D, Cauley JA, Cummings SR, LeBlanc ES, Laughlin GA, Nielson CM, et al. Sex hormones, sex hormone binding globulin, and vertebral fractures in older men. Bone 2016; 84:271-8; PMID:26776261; https://doi.org/10.1016/j.bone.2016.01.009

[89] Tajar A, Huhtaniemi IT, O'Neill TW, Finn JD, Pye SR, Lee DM, Bartfai G, Boonen S, Casanueva FF, Forti G, et al. Characteristics of androgen deficiency in late-onset hypogonadism: results from the European Male Aging Study (EMAS). J Clin Endocrinol Metabol 2012; 97:1508-16; https://doi.org/10.1210/jc.2011-2513

[90] Tajar A, Forti G, O’Neill TW, Lee DM, Silman AJ, Finn JD, Bartfai G, Boonen S, Casanueva FF, Giwercman A, et al. Characteristics of secondary, primary, and compensated hypogonadism in aging men: evidence from the European Male Ageing Study. J Clin Endocrinol Metabol 2010; 95:1810-8; https://doi.org/10.1210/jc.2009-1796

[91] Svardberg J, Midby M, Bonaa KH, Sundsfjord J, Joakimsen RM, Jorde R. The associations of age, lifestyle factors and chronic disease with testosterone in men: the Tromso Study, Euro J Endocrinol / Euro Federat Endocrin Soc 2003; 149:145-52; https://doi.org/10.1530/eje.0.1490145

[92] O’Connor DB, Lee DM, Corona G, Forti G, Tajar A, O’Neill TW, Pendleton N, Bartfai G, Boonen S, Casanueva FF, et al. The relationships between sex hormones and sexual function in middle-aged and older European men. J Clin Endocrinol Metabol 2011; 96:E1577-87; https://doi.org/10.1210/jc.2010-2216

[93] Kupelian V, Shabsigh R, Travison TG, Page ST, Araujo AB, McKinlay JB. Is there a relationship between sex hormones and erectile dysfunction? Results from the Massachusetts Male Aging Study. J Urol 2006; 176:2584-8; PMID:17085164; https://doi.org/10.1016/j.juro.2006.08.020

[94] Hall SA, Shackelton R, Rosen RC, Araujo AB. Risk factors for incident erectile dysfunction among community-dwelling men. J Sex Med 2010; 7:712-22; PMID:19929915; https://doi.org/10.1111/j.1743-6109.2009.01600.x

[95] Pye SR, Huhtaniemi IT, Finn JD, Lee DM, O’Neill TW, Tajar A, Bartfai G, Boonen S, Casanueva FF, Forti G, et al. Late-onset hypogonadism and mortality in aging men. J Clin Endocrinol Metabol 2014; 99:1357-66; https://doi.org/10.1210/jc.2013-2052

[96] Travison TG, Morley JE, Araujo AB, O’Donnell AB, McKinlay JB. The relationship between libido and testosterone levels in aging men. J Clin Endocrinol Metabol 2006; 91:2509-13; https://doi.org/10.1210/jc.2005-2508

[97] LeBlanc ES, Wang PY, Janowsky JS, Neiss MB, Fink HA, Yaffe K, Marshall LM, Lapidus JA, Stefanick ML, Orwell ES. Association between sex steroids and cognition in elderly men. Clin Endocrinol 2010; 72:393-403; PMID:19744108; https://doi.org/10.1111/j.1365-2265.2009.03692.x

[98] Mohr BA, Bhasin S, Link CL, O’Donnell AB, McKinlay JB. The effect of changes in adiposity on testosterone levels in older men: longitudinal results from the Massachusetts Male Aging Study. Euro J Endocrinol / Euro Federat Endocrin Soc 2006; 155:443-52; https://doi.org/10.1530/eje.1.02241

[99] Derby CA, Zilber S, Brambilla D, Morales KH, McKinlay JB. Body mass index, waist circumference and waist to hip ratio and change in sex steroid hormones: the Massachusetts Male Ageing Study. Clin Endocrinol 2006; 65:125-31; PMID:16817831; https://doi.org/10.1111/j.1365-2265.2006.02560.x

[100] Wu FC, Tajar A, Pye SR, Silman AJ, Finn JD, O’Neill TW, Bartfai G, Casanueva F, Forti G, Giwercman A, et al. Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study. J Clin Endocrinol Metabol 2008; 93:2737-45; https://doi.org/10.1210/jc.2007-1972

[101] Viken T, Schirmer H, Njolstad I, Svartberg J. Low testosterone and sex hormone-binding globulin levels and high estradiol levels are independent predictors of type 2 diabetes in men. European journal of endocrinology; European Federation of Endocrine Societies 2010; 162:747-54

[102] Svartberg J, Jenssen T, Sundsfjord J, Jorde R. The associations of endogenous testosterone and sex hormone-binding globulin with glycosylated hemoglobin levels, in community dwelling men. Tromso Study. Diab Metab 2004; 30:29-34; https://doi.org/10.1016/S1262-3636(07)70086-1

[103] Agledahl I, Skjaerpe PA, Hansen JB, Svartberg J. Low serum testosterone in men is inversely associated with non-fasting serum triglycerides: the Tromso study. Nutrit Metab Cardiovasc Dis: NMCD 2008; 18:256-62; PMID:17560771; https://doi.org/10.1016/j.numecd.2007.01.014

[104] Kupelian V, Page ST, Araujo AB, Travison TG, Bremner WJ, McKinlay JB. Low sex hormone-binding globulin, total testosterone, and symptomatic androgen deficiency are associated with development of the metabolic syndrome in nonobese men. J. Clin. Endocrinol. Metabol. 2006; 91:843-50; https://doi.org/10.1210/jc.2005-1326

[105] Barrett-Connor E. Lower endogenous androgen levels and dyslipidemia in men with non-insulin-dependent diabetes mellitus. Annals of internal medicine 1992; 117:807-11; PMID:1416554; https://doi.org/10.7326/0003-4819-117-10-807

[106] Barrett-Connor E, Von Muhlen DG, Kritz-Silverstein D. Bioavailable testosterone and depressed mood in older men: the Rancho Bernardo Study. J. Clin. Endocrinol. Metabol. 1999; 84:573-7; https://doi.org/10.1210/jcem.84.2.5495

[107] Stellato RK, Feldman HA, Hamdy O, Horton ES, McKinlay JB. Testosterone, sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men: prospective results from the Massachusetts male aging study. Diabetes care 2000; 23:490-4; PMID:10857940; https://doi.org/10.2337/diacare.23.4.490

[108] Chubb SA, Hyde Z, Almeida OP, Flicker L, Norman PE, Jamrozik K, Hankey GJ, Yeap BB. Lower sex hormone-
binding globulin is more strongly associated with metabolic syndrome than lower total testosterone in older men: the Health in Men Study. Euro J Endocrinol / Euro Federat Endocrine Soc 2008; 158:785-92; https://doi.org/10.1530/EJE-07-0893

[109] Yeap BB, Almeida OP, Hyde Z, Norman PE, Chubb SA, Jamrozik K, Hankey GJ, Flicker L. Healthier lifestyle predicts higher circulating testosterone in older men: the Health In Men Study. Clin Endocrinol 2009; 70:455-63; PMID:18691270; https://doi.org/10.1111/j.1365-2265.2008.03372.x

[110] Svarberg J, von Muhlen D, Schirmer H, Barrett-Connor E, Sundfjord J, Jorde R. Association of endogenous testosterone with blood pressure and left ventricular mass in men. The Tromso Study. Euro J Endocrinol / Euro Federat Endocrine Soc 2004; 150:65-71; https://doi.org/10.1530/eje.0.1500065

[111] Svarberg J, von Muhlen D, Mathiesen E, Joakimsen O, Bonaa KH, Stensland-Bugge E. Low testosterone levels are associated with carotid atherosclerosis in men. J Int Med 2006; 259:576-82; PMID:16704558; https://doi.org/10.1111/j.1365-2796.2006.01637.x

[112] Vikan T, Johnsen SH, Schirmer H, Njolstad I, Svarberg J, Vikan T, Johnsen SH, Schirmer H, Njolstad I, Svartberg J, von Muhlen D, Mathiesen E, Joakimsen O, Yeap BB, Almeida OP, Hyde Z, Norman PE, Chubb SA, Joakimsen O, Yeap BB, Almeida OP, Hyde Z, Norman PE, Chubb SA, Yeap BB, Almeida OP, Hyde Z, Norman PE, Chubb SA, Yeap BB, Almeida OP, Hyde Z, Norman PE, Chubb SA. Low free testosterone predicts frailty in older men: the health in men study. J Clin Endocrinol Metabol 2008; 93:1437-43; https://doi.org/10.1210/jc.2007-1792

[113] Hougaku H, Fleg JL, Najjar SS, Lakatta EG, Harman SM, Blackman MR, Metter EJ. Relationship between androgenic hormones and arterial stiffness, based on longitudinal hormone measurements. Am J Physiol Endocrinol Metab 2006; 290:E234-42; PMID:16159908; https://doi.org/10.1152/ajpendo.00334.2001

[114] Ohlsson C, Barrett-Connor E, Bhasin S, Orwoll EJ, Fleg JL, Najjar SS, Lakatta EG, Harman SM, Tobin JD, Blackman MR, Metter EJ. Interrelationships of serum testosterone and free testosterone index with FFM and strength in community-dwelling older men: the Concord Health and Ageing in Men project. J Clin Endocrinol Metabol 2014; 99:3310-8; https://doi.org/10.1210/jc.2014-1124

[115] Khaw KT, Barrett-Connor E. Blood pressure and endogenous testosterone in men: an inverse relationship. J Hypertension 1988; 6:329-32; PMID:3379300; https://doi.org/10.1097/00004872-198804000-00010

[116] Svarberg J, Jorde R. Endogenous testosterone levels and smoking in men. The fifth Tromso study. Int J Androl 2007; 30:137-43; https://doi.org/10.1111/j.1365-2605.2006.00720.x

[117] LeBlanc ES, Nielson CM, Marshall LM, Lapidus JA, Barrett-Connor E, Ensrud KE, Hoffman AR, Laughlin G, Ohlsson C, Orwoll ES. The effects of serum testosterone, estradiol, and sex hormone binding globulin levels on fracture risk in older men. J Clin Endocrinol Metabol 2009; 94:3337-46; https://doi.org/10.1210/jc.2009-0206

[118] Vanderschueren D, Pye SR, Venken K, Borghs H, Gaytant J, Huhtaniemi IT, Adams JE, Ward KA, Bartfai G, Casanueva FF, et al. Gonadal sex steroid status and bone health in middle-aged and elderly European men. Osteoporos Int 2010; 21:1331-9; PMID:20012940; https://doi.org/10.1007/s00198-009-1144-2

[119] Laughlin GA, Barrett-Connor E, Bergstrom J. Low serum testosterone and mortality in older men. J Clin Endocrinol Metabol 2008; 93:68-75; https://doi.org/10.1210/jc.2007-1792

[120] Barrett-Connor E, Laughlin GA, Li H, Nielson CM, Wang PY, Dam TT, Cauley JA, Ensrud KE, Stefanick ML, Lau E, et al. The association of concurrent vitamin D and sex hormone deficiency with bone loss and fracture risk in older men: the osteoporotic fractures in men (MrOS) study. J Bone Min Res: Off J Am Soc Bone Min Res 2012; 27:2306-13; PMID:22777902; https://doi.org/10.1002/jbmr.1697

[121] Ward KA, Pye SR, Adams JE, Boonen S, Vanderschueren D, Borghs H, Gaytant J, Gielen E, Bartfai G, Casanueva FF, et al. Influence of age and sex steroids on bone density and geometry in middle-aged and elderly European men. Osteoporos Int 2011; 22:1513-23; PMID:21052641; https://doi.org/10.1007/s00198-010-1437-5

[122] Hsu B, Cumming RG, Seibel MJ, Naganathan V, Blyth FM, Bleicher K, Dave A, Le Couteur DG, Waite LM, Handelsman DJ. Reproductive hormones and longitudinal change in bone mineral density and incident fracture risk in older Men: the concord health and aging in Men project. J Bone Min Res: Off J Am Soc Bone Min Res 2015; 30:1701-8; PMID:25736139; https://doi.org/10.1002/jbmr.2493

[123] Roy TA, Blackman MR, Harman SM, Tobin JD, Schrager M, Metter EJ. Interrelationships of serum testosterone and free testosterone index with FFM and strength in aging men. Am J Physiol Endocrinol Metab 2002; 283:E284-94; PMID:12110533; https://doi.org/10.1152/ajpendo.00334.2001

[124] Hsu B, Cumming RG, Naganathan V, Blyth FM, Le Couteur DG, Seibel MJ, Waite LM, Handelsman DJ. Longitudinal relationships of circulating reproductive hormone with functional disability, muscle mass, and strength in community-dwelling older men: the Concord Health and Ageing in Men project. J Clin Endocrinol Metabol 2014; 99:3310-8; https://doi.org/10.1210/jc.2014-1124

[125] O’Donnell AB, Travison TG, Harris SS, Tenover JL, McKinlay JB. Testosterone, dehydroepiandrosterone, and physical performance in older men: results from the Massachusetts Male Aging Study. J Clin Endocrinol Metabol 2006; 91:425-31; https://doi.org/10.1210/jc.2005-1227

[126] LeBlanc ES, Wang PY, Lee CG, Barrett-Connor E, Cauley JA, Hoffman AR, Laughlin GA, Marshall LM, Orwoll ES. Higher testosterone levels are associated with less loss of lean body mass in older men. J Clin Endocrinol Metabol 2011; 96:3855-63; https://doi.org/10.1210/jc.2011-0312

[127] Hyde Z, Flicker L, Almeida OP, Hankey GJ, McCaul KA, Chubb SA, Yeap BB. Low free testosterone predicts frailty in older men: the health in men study. J Clin Endocrinol Metabol 2010; 95:3165-72; https://doi.org/10.1210/jc.2009-2754

[128] Travison TG, Nguyen AH, Naganathan V, Stanaway FF, Blyth FM, Cumming RG, Le Couteur DG, Sambrook PN, Handelsman DJ. Changes in reproductive hormone concentrations predict the prevalence and progression
of the frailty syndrome in older men: the concord health and ageing in men project. J Clin Endocrinol Metab 2011; 96:2464-74; https://doi.org/10.1210/jc.2011-0143

[129] Caithon PM, Ensrud KE, Laughlin GA, Cauley JA, Dam TT, Barrett-Connor E, Fink HA, Hoffman AR, Lau E, Lane NE, et al. Sex hormones and frailty in older men: the osteoporotic fractures in men (MrOS) study. J Clin Endocrinol Metab 2009; 94:3806-15; https://doi.org/10.1210/jc.2009-0417

[130] Moffat SD, Zonderman AB, Metter EJ, Blackman MR, Harman SM, Resnick SM. Longitudinal assessment of serum free testosterone concentration predicts memory performance and cognitive status in elderly men. J Clin Endocrinol Metabol 2002; 87:5001-7; https://doi.org/10.1210/jc.2002-020419

[131] Zonderman AB. Predicting Alzheimer’s disease in the Baltimore longitudinal study of aging. J Geriatr Psychiatry Neurol 2005; 18:192-5; PMID:16306238; https://doi.org/10.1177/0891988705281863

[132] Moffat SD, Zonderman AB, Metter EJ, Kawas C, Blackman MR, Harman SM, Resnick SM. Free testosterone and risk for Alzheimer disease in older men. Neurology 2004; 62:188-93; PMID:14745052; https://doi.org/10.1212/WNL.62.2.188

[133] Barrett-Connor E, Goodman-Gruen D, Patay B. Endogenous sex hormones and cognitive function in older men. J Clin Endocrinol Metabol 1999; 84:3681-5.

[134] Yeap BB, Almeida OP, Hyde Z, Chubb SA, Hankey GJ, Jamrozik K, Flicker L. Higher serum free testosterone is associated with better cognitive function in older men, while total testosterone is not. The Health In Men Study. Clin Endocrinol 2008; 68:404-12.

[135] Ford AH, Yeap BB, Flicker L, Hankey GJ, Chubb SA, Handelsman DJ, Golledge J, Almeida OP. Progressive longitudinal study of testosterone and incident depression in older men: the health in Men study. Psychoneuroendocrinology 2016; 64:57-65; PMID:26615472; https://doi.org/10.1016/j.psyneuen.2015.11.012

[136] Fonda SJ, Bertrand R, O’Donnell A, Longcope C, McKinlay JB. Age, hormones, and cognitive functioning among middle-aged and elderly men: cross-sectional evidence from the Massachusetts Male Aging Study. J Gerontol A Biol Sci Med Sci 2005; 60:385-90; PMID:15860479; https://doi.org/10.1093/gerona/60.3.385

[137] Hsu B, Cumming RG, Waite LM, Blyth FM, Naganathan V, Le Couteur DG, Seibel MJ, Handelsman DJ. Longitudinal relationships between reproductive hormones and cognitive decline in older Men: the concord health and ageing in Men project. J Clin Endocrinol Metab 2015; 100:2223-30; https://doi.org/10.1210/jc.2015-01016

[138] Hyde Z, Norman PE, Flicker L, Hankey GJ, Almeida OP, McCaul KA, Chubb SA, Yeap BB. Low free testosterone predicts mortality from cardiovascular disease but not other causes: the Health in Men Study. J Clin Endocrinol Metabol 2012; 97:179-89; https://doi.org/10.1210/jc.2011-1617

[139] Araujo AB, Kupelian V, Page ST, Handelsman DJ, Bremner WJ, McKinlay JB. Sex steroids and all-cause and cause-specific mortality in men. Arch Int Med 2007; 167:1252-60; PMID:17592098; https://doi.org/10.1001/archinte.167.12.1252

[140] Vikan T, Schirmer H, Njolstad I, Svarthberg J. Endogenous sex hormones and the prospective association with cardiovascular disease and mortality in men: the tromso study. Euro J Endocrinol/ Euro Federat Endocrine Soc 2009; 161:435-42; https://doi.org/10.1530/EJE-09-0284

[141] Tvesten A, Vandenput L, Labrie F, Karlsson MK, Ljunggren O, Mellstrom D, Ohlsson C. Low serum testosterone and estradiol predict mortality in elderly men. J Clin Endocrinol Metabol 2009; 94:2482-8; https://doi.org/10.1210/jc.2008-2650

[142] Harman SM, Tsitouras PD. Reproductive hormones in aging men. I. Measurement of sex steroids, basal luteinizing hormone, and Leydig cell response to human chorionic gonadotropin. J Clin Endocrinol Metabol 1980; 51:35-40.

[143] Burns-Cox N, Gingell C. The andropause: fact or fiction? Postgrad Med J 1997; 73:553-6; PMID:9373594; https://doi.org/10.1136/pgmj.73.863.553

[144] Featherstone M, Hepworth M. The history of the male menopause 1848-1936. Maturitas 1985; 7:249-57; PMID:3908882; https://doi.org/10.1016/0378-5122(85)90047-7

[145] Schultheiss D, Jonas U, Mustelli S. Some historical reflections on the ageing male. World J Urol 2002; 20:40-4; PMID:12088189; https://doi.org/10.1007/s00345-002-0254-7

[146] Snyder PJ. Hypogonadism in elderly men—what to do until the evidence comes. N Engl J Med 2004; 350:440-2; PMID:14749451; https://doi.org/10.1056/NEJMp038207

[147] Corona G, Rastrelli G, Maggi M. Diagnosis and treatment of late-onset hypogonadism: systematic review and meta-analysis of TTR outcomes. Best Pract Res Clin Endocrinol Metab 2013; 27:557-79; PMID:24054931; https://doi.org/10.1016/j.beem.2013.05.002

[148] Petak SM, Nankin HR, Spark RF, Swerdloff RS, Rodriguez-Rigau LJ. American Association of Clinical Endocrinologists Medical Guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients--2002 update. Endocr Pract 2002; 8:440-56; PMID:1260010

[149] Nieschlag EB. H.M. Anamnesis and Physical Examination. In: Nieschlag EB, HM, Nieschlag S, ed. Andrology. Berlin: Springer, 2010:93-100.

[150] Ross A, Bhasin S. Hypogonadism: its prevalence and diagnosis. Urologic Clin North America 2016; 43:163-76; PMID:27132573; https://doi.org/10.1016/j. ucl.2016.01.002

[151] Ahern T, Swieciecka A, Eendebak RJ, Carter EL, Finn JD, Pye SR, O’Neill TW, Antonio L, Keevil B, Bartfai G, et al. Natural history, risk factors and clinical features of primary hypogonadism in ageing men: longitudinal data from the European male ageing study. Clin Endocrinol 2016; PMID:27374987

[152] Rastrelli G, Carter EL, Ahern T, Finn JD, Antonio L, O’Neill TW, Bartfai G, Casanueva FF, Forti G, Keevil B, et al. Development of and recovery from secondary hypogonadism in aging Men: prospective results from the EMAS. J Clin Endocrinol Metabol 2015; 100:3172-82; https://doi.org/10.1210/jc.2015-1571

[153] Kalyani RR, Gavini S, Dobbs AS. Male hypogonadism in systemic disease. Endocrinol Metab Clin North Am
Corona G, Rastrelli G, Maseroli E, Fralassi N, Sforza A, Forti G, Mannucci E, Maggi M. Low testosterone syndrome protects subjects with high cardiovascular risk burden from major adverse cardiovascular events. Andrology 2014; 2:741-7; PMID:25044637; https://doi.org/10.1111/j.2047-2927.2014.00241.x

[154] Lunenfeld B, Mskhalaya G, Zitzmann M, Arver S, Kalinchenko S, Tishova Y, Morgentaler A. Recommendations on the diagnosis, treatment and monitoring of hypogonadism in men. Aging Male: Off J Int Soc Study Aging Male 2015; 18:5-15; PMID:25657080; https://doi.org/10.3109/13685538.2015.1004049

[155] Kim S, Kwon H, Park JH, Cho B, Kim D, Oh SW, Lee CM, Choi HC. A low level of serum total testosterone is independently associated with nonalcoholic fatty liver disease. BMC Gastroenterol 2012; 12:69; PMID:22691278; https://doi.org/10.1186/1471-230X-12-69

[156] Balasubramanian V, Naing S. Hypogonadism in chronic obstructive pulmonary disease: incidence and effects. Curr Opin Pulmonary Med 2012; 18:112-7; PMID:22234275; https://doi.org/10.1097/MCP.0b013e32834feb37

[157] Mousavi SA, Kouchari MR, Samdani-Fard SH, Gilvae ZN, Arabi M. Relationship between serum levels of testosterone and the severity of chronic obstructive pulmonary disease. Tanaffos 2012; 11:32-5; PMID:25191426

[158] Svartrberg J, Schirmer H, Medbo A, Melbye H, Aasebo Mousavi SA, Kouchari MR, Samdani-Fard SH, Gilvae ZN, Arabi M. Elevated oestrogen and reduced testosterone levels in the serum of male septic shock patients. J Steroid Biochem 1988; 29:435-40; PMID:3374133; https://doi.org/10.1016/0022-4731(88)90254-3

[159] Travison TG, Shackelton R, Araujo AB, Hall SA, Williams RE, Clark RV, O’Donnell AB, McKinlay JB. The natural history of symptomatic androgen deficiency in men: onset, progression, and spontaneous remission. J Am Geriat Soc 2008; 56:831-9; PMID:18454749; https://doi.org/10.1111/j.1532-5415.2008.01679.x

[160] Rockwood K, Mitnitski A. Frailty defined by deficit accumulation and geriatric medicine defined by frailty. Clin Geriat Med 2011; 27:17-26; PMID:21093719; https://doi.org/10.1016/j.cger.2010.08.008

[161] Mitnitski A, Collerton J, Martin-Ruiz C, Jagger C, von Zglinicki T, Rockwood K, Kirkwood TB. Age-related frailty and its association with biological markers of ageing. BMC Med 2015; 13:161; PMID:26166298; https://doi.org/10.1186/s12916-015-0400-x

[162] Eichholzer M, Barbir A, Basaria S, Dobs AS, Feinleib M, Guallar E, Menke A, Nelson WG, Rifai N, Platzer EA, et al. Serum sex steroid hormones and frailty in older American men of the Third National Health and Nutrition Examination Survey (NHANES III). Aging Male: The Off J Int Soc Study Aging Male 2012; 15:208-15; PMID:22822787; https://doi.org/10.3109/13685538.2012.705366

[163] Tajar A, Lee DM, Pye SR, O’Connell MD, Ravindrarajah R, Gielen E, Boonen S, Vanderschueren D, Pendleton N, Finn JD, et al. The association of frailty with serum 25-hydroxyvitamin D and parathyroid hormone levels in older European men. Age Ageing 2013; 42:352-9; PMID:23111338; https://doi.org/10.1093/ageing/afs162

[164] Ravindrarajah R, Lee DM, Pye SR, Gielen E, Boonen S, Vanderschueren D, Pendleton N, Finn JD, Tajar A, O’Connell MD, et al. The ability of three different
models of frailty to predict all-cause mortality: results from the European Male Aging Study (EMAS). Arch Gerontol Geriat 2013; 57:360-8; PMID:23871598; https://doi.org/10.1016/j.archger.2013.06.010

[178] Vitale G, Cesari M, Mari D. Aging of the endocrine system and its potential impact on sarcopenia. Euro J Int Med 2016.

[179] Keevil VL, Romero-Ortuno R. Ageing well: a review of sarcopenia and frailty. Proc Nutrit Soc 2015; 74:337-47; PMID:26004622; https://doi.org/10.1017/S0029665115002037

[180] Angulo J, El Assar M, Rodriguez-Manas L. Frailty and sarcopenia as the basis for the phenotypic manifestation of chronic diseases in older adults. Mol Aspects Med 2016; 50:1-32; PMID:27370407; https://doi.org/10.1016/j.mam.2016.06.001

[181] Basualto-Alarcon C, Varela D, Duran J, Maass R, Estrada M. Sarcopenia and androgens: a Link between Pathology and Treatment. Front Endocrinol 2014; 5:217; PMID:25566189

[182] El-Serafi AT, Osama S, El-Zalat H. IM EL-D. Dysregulation of male sex hormones in chronic hepatitis C patients. Andrologia 2016; 48:82-6; PMID:25912488; https://doi.org/10.1111/and.12425

[183] Trojan TH, Lishnak TS, Heiman D. Epididymitis and orchitis: an overview. Am Fam Physician 2009; 79:583-7; PMID:19378875

[184] El-Serafi AT, Osama S, El-Zalat H. IM EL-D. Dysregulation of male sex hormones in chronic hepatitis C patients. Andrologia 2016; 48:82-6; PMID:25912488; https://doi.org/10.1111/and.12425

[185] Deeks SG. HIV infection, inflammation, immunosenescence, and aging. Annu Rev Med 2011; 62:141-55; PMID:20953306; https://doi.org/10.1146/annurev-med-042909-093756

[186] Rochira V, Zirilli L, Orlando G, Santi D, Brigante G, Diazza C, Carli F, Carani C, Guaraldi G. Premature decline of serum total testosterone in HIV-infected men in the HAART-era. PLoS One 2011; 6:e28512; PMID:22174826; https://doi.org/10.1371/journal.pone.0028512

[187] Sikaris K, McLachlan RI, Kazlauskas R, de Kreter D, Holden CA, Handelsman DJ. Reproductive hormone reference intervals for healthy fertile young men: evaluation of automated platform assays. J Clin Endocrinol Metab 2005; 90:5928-36; https://doi.org/10.1210/jc.2005-0962

[188] Yeap BB, Alfonso H, Chubb SA, Handelsman DJ, Hankey GJ, Norman PE, Flicker L. Reference ranges and determinants of testosterone, dihydrotestosterone, and estradiol levels measured using liquid chromatography-tandem mass spectrometry in a population-based cohort of older men. J Clin Endocrinol Metab 2012; 97:4030-9; https://doi.org/10.1210/jc.2012-2265

[189] Kloner RA, Carson C, 3rd Dobs A, Kopecky S, Mohler ER, 3rd. Testosterone and cardiovascular disease. J Am College Cardiol 2016; 67:545-57; PMID:26846952; https://doi.org/10.1016/j.jacc.2015.12.005

[190] Corona G, Isidori AM, Buvat J, Aversa A, Rastrelli G, Hackett G, Rochira V, Sforza A, Lenzi A, Mannucci E, et al. Testosterone supplementation and sexual function: a meta-analysis study. J Sex Med 2014; 11:1577-92; PMID:24697970; https://doi.org/10.1111/jsm.12536

[191] Basaria S, Coviello AD, Travison TG, Storer TW, Farwell WR, Jette AM, Eder R, Tennenst R, Ulooor J, Zhang A, et al. Adverse events associated with testosterone administration. N Engl J Med 2010; 363:109-22; PMID:20592293; https://doi.org/10.1056/NEJMoa1000485

[192] Finkle WD, Greenland S, Ridgeway GK, Adams JL, Frasco MA, Cook MB, Fraumeni JF, Jr., Hoover RN. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS One 2014; 9:e85805; PMID:24489673; https://doi.org/10.1371/journal.pone.0085805

[193] Vigen R, O’Donnell CI, Baron AE, Grunwald GK, Maddox TM, Bradley SM, Barqawi A, Woning G, Wierman ME, Plomondon ME, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA 2013; 310:1829-36; PMID:24193080; https://doi.org/10.1001/jama.2013.280386

[194] Corona G, Maseroli E, Rastrelli G, Isidori AM, Sforza A, Mannucci E, Maggi M. Cardiovascular risk associated with testosterone-boosting medications: a systematic review and meta-analysis. Expert Opin Drug Saf 2014; 13:1327-51; PMID:25139126; https://doi.org/10.1517/14740338.2014.950653

[195] Calof OM, Singh AB, Lee ML, Kenny AM, Urban RJ, Tenover JL, Bhasin S. Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci 2005; 60:1451-7; PMID:16339333; https://doi.org/10.1093/gerona/60.11.1451

[196] Haddad RM, Kennedy CC, Caples SM, Tracz MJ, Bolona ER, Sideras K, Uraga MV, Erwin PJ, Montori VM. Testosterone and cardiovascular risk in men: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin Proc 2007; 82:29-39; PMID:17285783; https://doi.org/10.1016/S0025-6196(11)60964-6

[197] Fernandez-Balsells MM, Murad MH, Lane M, Lampropulos JF, Albuquerque F, Mullan RJ, Elamin MB, Gallegos-Orozco JF, Wang AT, et al. Clinical review 1: adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metabol 2010; 95:2560-75; https://doi.org/10.1210/jc.2009-2575

[198] Xu L, Freeman G, Cowling BJ, Schooling CM. Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of randomized placebo-controlled trials. BMC Med 2013; 11:108; PMID:23597181; https://doi.org/10.1186/1741-7015-11-108

[199] Same RV, Bell DL, Rosenthal SL, Marcell AV. Sexual and reproductive health care: adolescent and adult men’s willingness to talk and preferred approach. Am J Prevent Med 2014; 47:175-81; PMID:24951042; https://doi.org/10.1016/j.amepre.2014.03.009

[200] Hughes AK, Wittmann D. Aging sexuality: knowledge and perceptions of preparation among U.S. primary care providers. J Sex Marital Ther 2015; 41:304-13; PMID:24927190; https://doi.org/10.1080/0092623X.2014.889056

[201] Stenholm S, Metter EJ, Greenland S, Adams JL, Finkle WD, Greenland S, Ridgeway GK, Adams JL, Frasco MA, Cook MB, Fraumeni JF, Jr., Hoover RN. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS One 2014; 9:e85805; PMID:24489673; https://doi.org/10.1371/journal.pone.0085805

[202] Sarcopenia and androgens: a Link between Pathology and Treatment. Front Endocrinol 2014; 5:217; PMID:25566189

[203] Haddad RM, Kennedy CC, Caples SM, Tracz MJ, Bolona ER, Sideras K, Uraga MV, Erwin PJ, Montori VM. Testosterone and cardiovascular risk in men: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin Proc 2007; 82:29-39; PMID:17285783; https://doi.org/10.1016/S0025-6196(11)60964-6
testosterone and longevity in the Baltimore Longitudinal Study of Aging. Aging Clin Exp Res 2011; 23:153-8; PMID:21743292; https://doi.org/10.1007/BF03351078

[202] Austad SN, Fischer KE. Sex Differences in Lifespan. Cell Metabol 2016; 23:1022-33; PMID:27304504; https://doi.org/10.1016/j.cmet.2016.05.019

[203] Nieschlag E, Nieschlag S, Behre HM. Lifespan and testosterone. Nature 1993; 366:215; PMID:8232579; https://doi.org/10.1038/366215a0

[204] Bale TL, Epperson CN. Sex differences and stress across the lifespan. Nat Neurosci. 2015; 18:1413-20; https://doi.org/10.1038/nn.4112